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Smertemåling i palliativ medisin: Validering av metoder for smertemåling ved 
selvrapportering og ved standardisert registrering av smerteatferd 
Smerte er et hovedsymptom blant kreftpasienter og flere studier har påpekt viktigheten av 
valid smertemåling for å kunne gi adekvat smertebehandling. Smerte er et subjektivt symptom 
og den enkelte pasients selvrapporterte smerte er derfor den viktigste komponenten i 
smertemålinger. Det finnes en rekke måleinstrumenter for smerte og European Association 
for Palliative Care (EAPC) anbefaler multidimensjonale målinger ved Brief Pain Inventory 
(BPI).
Mange pasienter får redusert kognitiv funksjon mot slutten av sykdomsløpet. For pasienter 
som ikke kan rapportere smerter selv, vil skjemaer for standardiserte registreringer av tegn på 
smerte utfylt av helsepersonell og/eller pårørende være et nødvendig alternativ. Doloplus-2 er 
et anbefalt verktøy for slike smerteregistreringer, men det finnes lite empirisk materiale om de 
psykometriske egenskapene. 
Hovedmålet med prosjektet var å fremskaffe ny kunnskap om smertemåling i palliativ 
medisin. En del av dette var å vurdere hvilke smertedimensjoner som er relevante for 
smertemåling i palliativ pleie og videre å evaluere to av de mest anbefalte smertemålene: BPI 
for selvrapportert smerte og Doloplus-2 for observasjonsbasert smertemåling. 
Et panel på seks eksperter i palliativ medisin anbefalte at et optimalt smertemål skal dekke 
smertedimensjonene intensitet, temporært mønster, behandlingseffekt samt lindrende og 
forverrende faktorer, lokalisering og smertens innvirkning på funksjonsnivå. Ingen av dagens 
smertemål dekker alle disse dimensjonene på en tilfredsstillende måte. 
For å utforske hvordan kreftpasienter rapporterer smertens innvirkning på funksjonsnivå ved 
BPI testet vi BPI i en pasientgruppe med fremskreden kreftsykdom og i en med kroniske, 
ikke-kreftrelaterte smerter. Smertemålene fra de to populasjonene ble sammenliknet og vi fant 
at mens kreftpasientene rapporterte at smerter i høy grad påvirket deres fysiske funksjon, anga 
de kroniske smertepasientene at smerter i første rekke påvirket deres psykologiske tilstand. 
Resultatene tydet dessuten på at kreftpasientene fant det vanskelig å si om deres nedsatte 
funksjonsnivå skyldtes smerte eller kreftsykdom. 
Doloplus-2 ble oversatt til norsk og ble vurdert som brukervennlig for klinisk bruk. I 
pilotstudien var kriterievaliditeten tilfredsstillende. Hovedstudien viste imidlertid at Doloplus-
2 er for lite smertespesifikt og krever kompetanse i å vurdere atferd som skyldes smerte og 
atferd som er forbundet med angst, forvirring og andre demensrelaterte faktorer. 
Oppsummert viser avhandlingen at de tilgjengelige smertemålene har vesentlige mangler og 
videre forskning er nødvendig for å forbedre smertemål for klinikk og forskning. 
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“When the right thing can only be measured poorly, it tends to cause the wrong thing 
to be measured only because it can be measured well. And it is often much worse to 
have good measurement of the wrong thing –especially when, as is so often the case, 
the wrong thing will in fact be used as an indicator of the right thing –than to have 
poor measurement of the right thing” (Tukey 1979). 
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Study objectives 
The overall objective of this thesis was to improve our knowledge of pain assessment 
of particular relevance for palliative care. We wanted to evaluate two highly 
recommended tools for pain assessment in PC patients; the BPI for self-report and the 
Doloplus-2 for behavioural rating of pain. The research questions were as follows: 
1. Which dimensions of pain are most relevant for self-reported pain assessment 
in PC (Paper I)? 
a. Which pain dimensions are assessed by existing tools for pain 
assessment? 
b. Is the content validity of the existing tools satisfactory in a PC setting? 
2. How do patients in PC report pain’s interference with functions as measured 
by the BPI (Paper II)? 
a. Does the BPI discriminate between interference on functions caused by 
disease and such interference caused by pain? 
3. Does the Doloplus-2 have criterion validity in patients who are unable to self-
report pain due to cognitive impairment (Papers III & IV)? 
a. Which pain behaviours, as measured by the Doloplus-2, contribute 
most in behavioural pain assessment (Paper III)? 
b. Is the Doloplus-2 feasible in clinical use (Papers III & IV)? 
c. Does the Doloplus-2 have satisfactory inter-rater reliability (Paper IV)? 
d. What constitutes a valid pain criterion in those unable to self-report 
pain (Paper IV)? 
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1. Introduction 
The Norwegian cancer incidence was 24488 in 2006 (Cancer Registry of Norway 
2007). In Norway the survival from cancer disease has slightly increased over the last 
years, and the most recent report shows five-year relative survival probabilities after a 
cancer diagnosis at 57% for male and 63% for female patients (Cancer Registry of 
Norway 2007). The incurable patients will eventually require palliative care (PC), and 
for these patients success in treatment will be measured by degree of symptom control 
and levels of health related quality of life (HRQOL). 
Pain is reported to be one of the most frequent and disturbing symptoms in cancer 
patients. Pain is of subjective nature and it is addressed through the HRQOL-concept. 
Despite massive research on pain treatment and assessment, studies still demonstrate 
that many patients receive less than optimal treatment. In order to improve cancer 
pain treatment one challenge is to find and use assessment tools that are able to assess 
the important aspects of pain in frail patients with several concurrent symptoms often 
combined with deteriorating cognitive function. 
The present study was part of a larger European multi-centre study, the ”Palliative 
Assessment Tool -Computerized” (PAT-C) which was organized and conducted 
through the European Association of Palliative Care Research Network (EAPC 2006). 
The overall objective was to improve clinical symptom management and individual 
assessment of symptoms while minimizing the burden of the patient by developing a 
computer-based tool for self-reported assessment of symptoms and functioning in PC 
patients. Pain was one of the symptoms to be assessed, the others were physical 
functioning, depression, cognitive functioning and fatigue. The PAT-C project was 
refined in a new application to EU which granted the research group money for a five 
years project in PC. The main focus in this thesis is on pain in patients with advanced 
disease who receive PC, either in a hospital situated PC unit or in a nursing home. 
1.1 Palliative care 
Palliative care (PC) was first recognized as a medical speciality in Great Britain in 
1987 and defined as: 
11
“the study and management of patients with active, progressive, far-advanced disease 
for whom the prognosis is limited and the focus of care is the quality of life” (Doyle et 
al. 1993). 
The World Health Organization (WHO) published the following definition of PC in 
2002:
“Palliative care is an approach that improves the quality of life of patients and their 
families facing the problems associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and impeccable 
assessment and treatment of pain and other problems, physical, psychosocial and 
spiritual” (Sepulveda et al. 2002).
The modern school of PC builds on the work of the hospice movement and especially 
the pioneering work of Dame Cicely Saunders (Doyle et al. 1993). 
Medical care can be divided into the two categories of curative treatment and PC. The 
categorization is based on the intention behind the treatment, but will often overlap in 
the care situation (Kaasa 1998). Palliative care is not medicine exclusively for the 
dying. Patients who receive treatment with a curative intention may also benefit from 
palliative treatment. However, PC and the hospice movement are most central in care 
for patients with advanced disease. While the mainstream hospital part of medicine 
often regards death as a medical failure, palliative medicine and the hospice 
movement endorse death as a meaningful process and strive for the maintenance of 
dignity and quality of life in the last part of life (Randall and Downie 2006). Palliative 
care research is still in its early development (Jordhoy et al. 1999), but it has received 
rapidly increasing attention recently. 
In this thesis, PC is not strictly limited to care for dying patients in a very late or 
terminal phase, but understood as the part of medicine that focuses on symptom 
alleviation in seriously diseased patients. A main focus in PC is symptom control to 
increase or conserve the patient’s HRQOL. The positive effects of treatment will be 
weighted towards side-effects to reach an optimal balance, often described in terms of 
highest possible level of HRQOL. 
Cancer is the primary diagnosis in most patients in Norwegian PC units. These 
patients report high levels of several co-occurring symptoms (Kaasa 1998;Teunissen 
et al. 2007) and cognitive failure is also common (Radbruch et al. 2000;Tuma and 
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DeAngelis 2000). A study indicated that the median number of symptoms per cancer 
patient upon initial referral to a PC unit was 11 (range: 1 – 27, N=1000), and that the 
10 most prevalent symptoms were pain, fatigue, weakness, anorexia, lack of energy, 
dry mouth, constipation, early satiety, dyspnea, and weight loss (Walsh et al. 2000). A 
recent study confirms the high number of co-occuring symptoms in advanced cancer 
patients. At admission to a PC hospital unit these patients (N = 77) experienced 
fatigue (97%), cachexia (96%), pain (88%), constipation (69%), nausea and/or 
vomiting (53%), and dyspnea (49%) (Tsai et al. 2006). It is a general challenge to 
assess subjective symptoms in frail-old patients suffering from several symptoms and 
of whom several have reduced cognitive function, but it is possible to achieve rather 
complete self-reported data even in those with highly pronounced symptomatology 
(Stromgren et al. 2002). 
Norwegian nursing home patients are usually older than 80 years, they have an 
average of 5 - 7 serious diagnoses and 95% of the inpatients will eventually die in the 
nursing home (Husebø and Husebø 2005). A Norwegian study focused on the place of 
death for cancer patients and found that those who died in nursing homes were older 
(median 77 years), more often living alone (58%), the majority were females (66%), 
they reported more disabilities from other causes than cancer, and had poorer 
performance status (Karnofsky index) compared to those who died in hospitals or at 
home (Jordhoy et al. 2003). 
Palliative care units at hospitals and nursing homes share similar challenges leading to 
the national five year project: Hospice and palliative care for the elderly. The aim 
was to achieve better PC for all elderly regardless of age, diagnoses and place of 
residence (Husebø and Husebø 2005). From 2004 project-based annual grants have 
been given to establish and operate palliative beds or units in nursing homes, but no 
permanent arrangement has yet been set up to secure these beds and competence 
(Kaasa et al. 2007). The recently developed Trondheim model is also trying to close 
the gap between hospital PC units and nursing homes by establishing two short-term 
units specializing in palliative treatment and care at an intermediary level between 
ordinary nursing homes and hospitals (Garåsen et al. 2005). In the National Strategy 
for Cancer 2006-2009 one of the major challenges is to organize and finance new and 
existing PC units and beds in nursing homes (Helse og Omsorgsdepartementet 2006). 
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1.2 Pain 
During the past 60 years, pain assessment and management have become increasingly 
recognised as important. The understanding of pain as a subjective experience is 
equally “recent”. Melzack and Wall’s publication of the gate control theory in 1965 
(Melzack and Wall 1965) was a breakthrough in the understanding of the pain 
phenomenon. Previously, pain had been seen by most as a more or less objective by-
product of tissue damage and disease (Loeser 2001). The gate control theory
postulated that the pain experience consists of three different components: sensory-
discriminative, motivational-affective, and cognitive-evaluative: 
 “It is assumed that these three categories of activity interact with one another to 
provide perceptual information on the location, magnitude, and spatiotemporal 
properties of the noxious stimuli; a motivational tendency toward escape or attack; 
and cognitive information based on past experiences and probability of outcome of 
different response strategies. All three forms of activity can then influence motor 
mechanisms responsible for the complex pattern of overt responses that characterise 
pain.”(Melzack and Katz 2001) pp.35-36). 
The heightened level of attention towards pain was followed by the formation of The 
International Association for the Study of Pain (IASP) in 1973. IASP proposed the 
following pain definition which has become widely recognized: 
“Pain is an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage.
Notes:
The inability to communicate verbally does not negate the possibility that an individual is experiencing 
pain and is in need of appropriate pain-relieving treatment. 
Pain is always subjective. Each individual learns the application of the word through experiences 
related to injury in early life. Biologists recognize that those stimuli which cause pain are liable to 
damage tissue. Accordingly, pain is that experience we associate with actual or potential tissue 
damage. It is unquestionably a sensation in a part or parts of the body, but it is also always unpleasant 
and therefore also an emotional experience. Experiences which resemble pain but are not unpleasant, 
e.g., pricking, should not be called pain. Unpleasant abnormal experiences (dysesthesias) may also be 
pain but are not necessarily so because, subjectively, they may not have the usual sensory qualities of 
pain” (IASP 2005). 
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According to the Gate control theory and the IASP definition, the pain experience is 
understood as a complex perceptual and cognitive process in which both biology and 
psychology influence each other. Individual evaluative and response patterns of both 
biological and psychological origin make pain a subjective symptom. A simple 
theoretical model of nociceptive pain is illustrated in figure 1. It should be noticed 
that the injured person has to define the experienced sensation as pain in order to get it 
measured. 
Figure 1, pain 
Damage of tissue              Nociception               CNS/Brain               Perceived Pain               Expressed pain 
                                                                                                                                                                
                                                     Personality and biological components      Cognition                      Measurement 
                                                                                                                                                                 
                                                                         Psychological stress                                            Pain, as measured 
Figure 1 describes the pain phenomenon from the initial damage of tissue, through 
the complex biological and psychological processing, to final assessment (Enhanced 
version of figure presented by (Kaasa 1998) p.303). 
More recently Melzack has proposed a more general “neuromatrix model” reducing 
the importance of the gate control in the dorsal horns of the spinal column and 
increasing the importance of the individual’s genes and processes in the brain 
(Melzack 1999;McDowell 2006). Certain brain mechanisms recognize the body as a 
whole. They constitute a widespread network of neurons with feedback loops within 
the cortex, thalamus and the limbic system. A pain stimulus will travel in repeated 
cycles between these systems where perception of the stimulus will be blended with 
cognition, emotions, personality and the person’s previous experiences and learning 
effects related to pain. The result is an individual neurosignature based on the 
individual’s biological (genes) disposition of reacting to stress stimuli that in turn 
characterizes the person’s basic way of reacting to a pain stimulus (McDowell 2006). 
Pain is the most common symptom leading people to seek medical treatment in the 
USA (Turk and Melzack 2001). Pain is the second most prevalent symptom and the 
most distressing one among cancer patients receiving PC (Brescia et al. 1992;Perron 
and Schonwetter 2001;Kaasa and Loge 2003;Stromgren et al. 2006). Approximately 
70% of cancer patients with metastatic disease experience pain (Breitbart and Payne 
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2000). A recent Norwegian prevalence study (N=309), measuring pain for the past 24 
hours at a single fixed day at 13 Norwegian hospitals, found that 51% of the cancer 
patients had pain (Holtan et al. 2005). The pain prevalence varies greatly between 
different types of cancer and also within the cancer disease trajectory. Only 5% of the 
leukaemia patients experience pain compared to 85% of the patients with bone or 
cervix cancer (Breitbart and Payne 2000). Divergent results are published on the 
relationship between gender, age and the prevalence of cancer pain. A recent 
Norwegian study found no significant differences on pain from gender or age (Holtan 
et al. 2005). Holtan et al. (2005) also addressed the prevalence of cancer pain among 
hospitalized cancer patients and discovered that 39% of those who had severe pain 
(NRS-11  5) were not on opioids. Twenty-seven of the patients (N=309) reported 
high pain intensity while not receiving any analgesics, and 22 patients had more than 
six episodes of breakthrough pain a day, indicating under-treatment with analgesics 
(Holtan et al. 2005). The study concluded that in spite of increasing attention and 
knowledge with regard to pain management, patients in general do still not receive 
adequate palliation, and that better systematic assessment is recommended (Holtan et 
al. 2005). 
A study by Ross and Crook found that 76% of the elderly patients who received 
nursing assistance at home experienced pain (Ross and Crook 1998), Ferrell et al.
found that 71% of the nursing home residents experienced pain during the past week 
(Ferrell et al. 1990), Weiner et al. found pain problems in 68% of the nursing home 
residents (Weiner et al. 1998), and a study by Parmelee et al. documented pain 
complaints in 47% of nursing home residents (Parmelee et al. 1993). It has recently 
been stated that 45% to 80% of nursing home patients experience clinically significant 
pain that is insufficiently treated (American Geriatrics Society 2002). In addition to 
cancer pain, older people are more likely to suffer from chronic pain conditions from 
arthritis, bone and joint disorders and back (American Geriatrics Society 2002). 
1.3 Pain assessment 
Pain control is regarded as a crucial part of PC (Caraceni et al. 2002;Cella et al. 2003) 
and pain assessment is a premise to understand and adequately treat pain (Camp-
Sorrell and O'Sullivan 1991;McCaffery 1992;Turk and Melzack 2001). Development 
of efficient assessment tools for diagnosis, audit, and the monitoring of individual 
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care and population effects of regiments of treatment are consequently central for both 
the practice and research in PC. 
In order to provide an assessment tool for all situations, it should be short and easy to 
complete as most patients will be significantly physically and mentally reduced 
during the progress of disease. Furthermore, the tool should ideally be applicable in 
the cognitively impaired and for patients’ self-reports and proxy rating. 
Pain assessment is based upon the patients’ self-report of their pain experiences, 
psychophysiological assessments or by observations of pain behaviour. Tools for pain 
assessment should be standardized and the psychometric performance of the tools 
should be documented for use in the given population. Pain assessments in children 
and adults have usually been treated separately. The present focus is pain assessment 
in adults by self-report or by behavioural assessment.  
Subjective experiences like pain are challenging to assess and quantify into 
standardized scores. 
“The frequency, severity, and disruptiveness of pain in cancer are matters of great 
interest to pain researchers and clinicians alike. For health care personnel, 
assessment and management of pain represents frustrating clinical problems” (Daut
et al. 1983) p. 197).
This statement is from 1983, but still relevant. In a study among 897 physicians 
providing care for cancer patients, poor pain assessment was found to be the most 
important barrier against appropriate pain management (Von Roenn et al. 1993), and 
in a recent report the National Institute of Health states that better pain assessment is 
needed (Patrick et al. 2004). Cleeland warned about undertreatment of cancer pain in 
elderly patients in 1998 (Cleeland 1998). Studies demonstrate that pain is still 
unsatisfactorily managed in cancer patients and inadequate pain assessment is 
suggested as one of the contributing factors (Caraceni and Portenoy 1999;Higginson 
et al. 2003;Holtan et al. 2005). With this background in mind, it is evident that more 
efforts are needed in order to improve the assessment of pain so more optimal 
treatment can be offered. The research literature flourishes with different approaches 
to pain assessment and with different tools for this purpose. The first upcoming 
choices are usually between assessment tools based upon patients’ self-report or 
proxy ratings/behavioural assessments and between a unidimensional or a 
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multidimensional approach to pain. The tool should also be both valid in the given 
population and feasible for the purpose of the assessment. 
1.4 Assessment by self-report 
As pain is a subjective symptom, the patient’s self-report is regarded as the golden 
standard for assessment (Ingham and Portenoy 1998;Smith 2005). There is a wide 
variety of questionnaires differing in length and content (Jensen and Karoly 
2001;Jensen 2003). Most tools are paper based, and the patient fills in the most 
appropriate response alternative or an administrator interviews the patient and marks 
the responses. Recently, the paper and pencil methodology has been experimentally 
transferred into computerized questionnaires, which take advantage of computer 
technology in order to make adaptive tests (Cella et al. 2005;Bjorner et al. 2005). 
Patients receiving PC are often frail, and have deteriorating health and multiple 
symptoms. These factors impact on the possibility to conduct the pain assessment. 
Assessment tools for PC must be short and easy to understand as assessment burden is 
an important aspect in frail patients. Yet they need to be comprehensive enough to 
cover the complicated pain cases that may be experienced by patients with advanced 
disease. Self-report based pain assessment tools can roughly be divided into 
unidimensional tools that only target one pain dimension like intensity or quality and 
multidimensional tools that target more than one dimensions of pain such as intensity, 
pain’s interference with functions and temporal patterns. 
1.4.1 Unidimensional pain assessment 
The most frequently used unidimensional tools are single-item scales, usually a 
coloured analogue scale (CAS), numeric rating scale (NRS), verbal rating scale 
(VRS) or visual analogue scale (VAS) to measure pain intensity (here presented in 
alphabetical order): 
Coloured Analogue Scale 
The CAS is a device with a slider over a laying triangle varying from narrow (10 mm) 
and white at the end labelled “no pain” to wide (30 mm) and dark red at the end 
labelled “most pain” (Hicks et al. 2001). The patient’s score is displayed by the 
marker in numerical values at the back of the scale, usually 0 - 10. The CAS is 
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developed for pain assessment in children, but proved effective for elderly as well 
(Scherder and Bouma 2000). 
Numeric rating scales 
Several different NRS designs are available but they have all in common two anchor 
points with increasing numbers in-between. The anchor points are usually named no 
pain at the left end and worst possible pain at the right end. Between the anchor 
points are numbers for example from 0 - 10 or 0 - 100. The number of response 
alternatives is reflected in the name, for example NRS-11 referring to a scale with 
eleven response options (from 0 - 10). An advantage with the NRS is that it can be 
administered verbally. 
NRS-11: Please rate your pain by circling the one number that best describes your 
pain:
No pain   0     1     2     3     4     5     6     7     8     9     10   Worst possible pain 
Verbal Rating Scales 
The VRS consists of ranked word descriptors. The number of words is usually a trade 
off between sensitivity and complexity in completing the assessment, with four and 
five words as popular compromises (See table 1). Patients select the word that best 
describes their sensation. This can be achieved either by the patient marking the word 
or by interview. The VRS is considered as the most easily understandable of these 
scales, thus suitable for those unable to understand the NRS but still able to self-
report.
VRS-4: Please rate your pain 
1. No pain    2. Mild pain    3. Moderate pain    4. Severe pain 
19
Visual Analogue Scale 
The VAS is a straight 10 cm line between two anchor points usually named no pain
and worst possible pain. The patient is instructed to put a mark with a pencil at the 
line equivalent to the experienced pain intensity. The score is calculated by measuring 
the distance from the zero point (no pain) to the mark in millimetres. The VAS is a 
continuous scale, but still limited with start and end points. It is well documented that 
the VAS should be used with caution in elderly patients and in those with advanced 
sickness as it is more demanding to understand than scales such as VRS and NRS 
(Herr and Mobily 1993;Benesh et al. 1997;Gagliese 2001). 
VAS: Please cross the line at the point that best describes your pain 
No pain Worst possible pain 
The single-item scales are popular tools for unidimensional pain assessment. These 
instruments produce valid results and they are translated into many different 
languages (Caraceni et al. 2002). Studies suggest equally satisfactory predictive 
validity and compliance in all these scales in chronic pain populations (Jensen et al. 
1986), while patients with advanced cancer disease have higher completion rates 
using VRS and NRS compared to the VAS (Herr and Mobily 1993;Benesh et al. 
1997;Gagliese 2001). NRS is generally recommended as the most practical tool 
(Jensen et al. 1986;Chibnall and Tait 2001). Unidimensional tools with few items can 
be easy to use when the purpose is to assess pain intensity and relief. On the other 
hand, they say little about the nature of the pain experience, temporal aspects, causes 
and consequences for the patient. 
1.4.2 Multidimensional pain assessment 
Several authors have stressed that pain is multidimensional (Millard 1993;de Conno et 
al. 1994;Melzack and Katz 1994;Shannon et al. 1995;Zimmerman et al. 
1996;Caraceni et al. 1996;de Wit et al. 1999;Chung et al. 2000;Campbell 2003). 
Cancer pain has a nociceptive basis, but other influential factors call for a 
multidimensional understanding and assessment procedure (Millard 1993). Pain 
intensity is the most salient dimension but the report of pain is also related to cultural 
background, past experiences, the meaning of the situation, personality, level of 
arousal and emotions (Turk and Melzack 2001). Assessment of dimensions additional 
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to intensity is essential when the purpose is to capture the total pain problem. 
Dimensions like pain quality, a description of the sensory experience of the pain, and 
pain’s interference with different functions and QoL are commonly assessed 
dimensions among numerous others. 
The Expert Working Group (on pain) of the EAPC recommends the Short Form 
McGill Pain Questionnaire (SF-MPQ (Melzack 1987)) for characterization of pain 
syndromes and assessment of pain quality and the Brief Pain Inventory short form 
(BPI-sf (Pain Research Group at MD Anderson Cancer Centre 2006b)) is 
recommended for multidimensional assessment of pain (Caraceni et al. 2002). 
Consequently, those two tools constitute a standard for self-report based 
multidimensional cancer pain assessment. 
The McGill Pain Questionnaire including both the short form (SF-MPQ (Melzack 
1987)) and the standard version (MPQ (Melzack 1975)), are dictionaries in the 
language of pain. The MPQ is constructed to measure three dimensions of pain; 
sensory-discriminative; motivational-affective; and cognitive-evaluative (Melzack 
and Katz 1994). The construct is a lexical approach where words describing sensory 
qualities, affective qualities and a scale of evaluative words describing overall pain 
intensity (a verbal rating scale) are grouped together and the patient is instructed to 
mark the appropriate descriptors. The SF-MPQ is a widely used tool for assessing 
pain quality (diagnostic properties of pain) and the main component consists of 15 
adjectives that describe different pain sensations (4 affective and 11 sensory) 
(Melzack 1987;Melzack and Katz 2001). The patients are instructed to rate each 
descriptor on an intensity VRS-4, no pain - mild - moderate - severe. The present pain 
intensity is rated on the so called Present Pain Index which is a combination of a 
VRS-6 and a VAS (Melzack and Katz 2001). 
The Brief Pain Inventories (Cleeland 1991) are available as full version (Pain 
Research Group at MD Anderson Cancer Centre 2006a) and as short version BPI-sf 
(Pain Research Group at MD Anderson Cancer Centre 2006b). The tools measure 
pain intensity, pain location, effects from pain medication, and pain’s interference 
with functions. The full version Brief Pain Inventory also records patient’s illness 
history, temporal pattern, relieving and exacerbating factors, and pain quality. The 
BPIs are of the most frequently and widely used tools for multidimensional cancer 
pain assessment and BPI-sf has also been validated as a measure for cancer pain in 
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many cultures and languages (Caraceni et al. 1996;Wang et al. 1996;Uki et al. 
1998;Ger et al. 1999;Saxena et al. 1999;Radbruch et al. 1999;Mystakidou et al. 
2001;Klepstad et al. 2002;Badia et al. 2003;Yun et al. 2004). 
Even though the sf-MPQ and the BPI-sf are recommended for multidimensional 
assessment, they are also criticised. The Expert Working Group of the EAPC found 
the sf-MPQ was more demanding to use than other tools, an experience shared by 
others (Millard 1993;Caraceni et al. 2002;Campbell 2003). Furthermore, the Pain 
Rating Index (PRI) is problematic since descriptors assessing distinct pain qualities 
are combined into subscales and information concerning the specific pain qualities 
endorsed by the patients is lost (Holroyd et al. 1992). The recommended area of use 
for the MPQ is also limited to situations where researchers want to describe 
characteristics of different pain syndromes, according to the EAPC. 
The EAPC recommends the BPI-sf for general assessment in PC. Twycross et al.
(1996) presented a study on both BPI versions, the full and the short. The full version 
BPI was found troublesome to use and less than 60% of the patients completed all 
items. The study concluded by presenting three arguments against the full version 
BPI; too burdensome for the patient to complete; too burdensome for the clinician to 
analyse the “data mountain” created; and too difficult to interpret with a time frame 
of "in the last week", while the BPI-sf was judged as not comprehensive enough 
(Twycross et al. 1996) p.280). The Norwegian BPI-sf validation study questioned the 
validity of the interference scales. A concern was raised regarding the patients’ ability 
to report pain’s interference with functions without bias from decreased function 
caused by other factors (Klepstad et al. 2002), and this concern was documented in a 
recent study which indicated that patients have limited ability to make valid 
attributions of pain’s interference on functions using the BPI-sf (Stenseth et al. 2007). 
Cleeland, the constructor of the BPIs, reports findings from one study comparing the 
full version Brief Pain Inventory scores from oncology patients to patients with non 
cancer chronic pain (NCCP) (Cleeland 1989). He observed that almost all NCCP 
patients reported high pain intensity (ceiling), making such assessment problematic. 
Pain’s interference was on the other hand more evenly distributed in both patient 
populations. Cleeland did not explore the possible causes for the differences in the 
two patient populations. Recently, in two studies the BPI-sf was validated for pain 
assessment in patients with NCCP (Tan et al. 2004;Keller et al. 2004), but none of 
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these studies addressed possible differences in how patients with cancer and NCCP 
report pain using the BPI-sf. Pain is different in these two populations. Comparison of 
pain reports from both groups can disclose new aspects regarding the content validity of 
the BPIs - is pain’s interference with functions reported similarly by both groups or must 
patients’ diagnoses be taken into account. 
As described, the BPIs are highly recommended and frequently used tools for self-
reported multidimensional cancer pain. However, studies report that it may be too 
demanding to use for patients in PC and there is no evidence that the pain dimensions 
in the BPIs are the most informative to assess. Multidimensional assessment is 
recommended by many, but to our knowledge, evidence-based information regarding 
the content of the pain assessment tools is too scarce. At present, we are not aware of 
any studies that have specifically addressed the content of pain assessment tools with 
specific relevance for cancer pain assessment in PC. Information on the relevance of 
the different pain dimensions is needed before recommendations on specific 
assessment tools can be given. 
1.5 Behavioural pain assessment 
As self-report of pain is regarded the gold standard, observational assessment of 
behaviour indicative of pain has come to be the preferred method only in patients who 
are unable to self-report, e.g. young children and those with cognitive failure 
(Prkachin et al. 1994). Cognitive impairment is common in patients with advanced 
disease. Between 50% and 71% of nursing home residents are cognitively impaired 
(Ferrell et al. 1995;Matthews and Dening 2002), and a Norwegian study reported 
dementia in over 75% of nursing home residents and in 21% of those above 75 years 
living at home (Engedal et al. 1988). A recent review reported prevalence rates in PC 
patients ranging from 14% to 44%, rising to 90% prior to death (Hjermstad et al. 
2004).
Several studies have investigated the cognitively impaired patients’ ability to self-
report pain using one or more methods for pain assessment (Smith 2005). However, 
these studies have excluded patients who were noncommunicative (Smith 2005). The 
development of formalized and systematic methods for behavioural pain assessment 
begun in the early eighties (Labus et al. 2003). The American Geriatrics Society 
(AGS) provides a guideline on the management of persistent pain in older persons 
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with severe dementia that are noncommunicative (American Geriatrics Society 2002). 
Such patients should be observed for nonverbal pain behaviours and changes in 
activity and function that may be suggestive of pain. The AGS gives no clear 
recommendations of specific tools for pain assessment, but highlights that this is an 
important area of ongoing research. It is stressed that the presentation of pain 
behaviours, particularly in those with dementia, can be quite variable (American 
Geriatrics Society 2002). For example, one patient might present with increased 
irritability and pacing, while another presents with withdrawal and refusal to eat. 
Consequently, it is very important to determine the patient's baseline behaviours and 
then monitor for changes over time that may indicate the presence of pain (American 
Geriatrics Society 2002). It should also be noted that some patients do not 
demonstrate pain typical behaviours when experiencing severe levels of pain 
(American Geriatrics Society 2002) e.g. a patient that presents “more and stronger” 
facial indicators with increasing pain may get a frozen facial expression when 
experiencing severe pain, while another patient presents even more facial expressions. 
Behavioural assessment of pain by observation rests upon three key assumptions 
(Villanueva et al. 2003): 
1. Facial expressions, verbalizations, changes in mental status, body posture, and 
movement patterns can indicate the presence of pain (Hurley et al. 1992;Weiner et al. 
1999;Hadjistavropoulos and Craig 2002;American Geriatrics Society 2002). 
2. Pain can interfere with activities of daily living (ADL), such as sleep, social 
activities, washing, dressing and eating (Cleeland 1991;Hurley et al. 1992;American 
Geriatrics Society 2002). 
3. Caregivers can reliably observe and rate such behaviours. 
The presence of pain behaviours is well accepted. The essential question is whether 
standardized observations of these are valid as indicators of pain since it may be a 
considerable problem to separate signal from noise. 
Behavioural assessment procedures commonly take place by one person observing 
and rating pain indicative behaviour in another person. Behaviour can provide 
indications of the presence of pain, information about pain location, severeness, and 
cause (Craig et al. 2001). Facial expressions are the most recognized and explored 
area of pain behaviours and studies have documented their validity and even that 
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different diseases may result in different facial expressions (Prkachin et al. 1994;Craig 
et al. 2001;Manfredi et al. 2003). Most efforts have been used on the Facial Action 
Coding System (FACS) which is an elaborated model of all the facial muscles that 
control the various actions that are identified as associated with pain (Ekman and 
Friesen 1978). The FACS can be used to validate the presence of pain behaviours by 
observers coding the facial expressions of people who are introduced to different pain 
stimuli or are in a known painful situation. A study of 28 patients complaining of 
chest pain demonstrated that all the patients with true myocardial infarctions (in 
opposition to those with other diagnoses) displayed similar patterns of facial 
expressions, like lowering the brow, pressing the lips, parting the lips, and turning the 
head left (Dalton et al. 1999). Pain behaviours can be divided into those that are 
intended to communicate pain to others e.g. calling for attention, and those that are 
performed to relieve pain like supporting a hurting arm. Most behavioural pain 
assessment tools encompass both behavioural types. Behavioural assessment may also 
be used in combination with self-report as a comprehensive evaluation of patients, for 
example in cases where there may be doubts with regard to the patients’ self-reports. 
Behavioural pain rating tools are seemingly rough measures aimed at the detection of 
pain, not the quantification of it. The number, degree, and frequencies of different 
pain behaviours may indicate the severeness of pain, but we are not aware of any 
validated tool for the assessment of pain interference or intensity by observations. An 
obvious obstacle for behavioural pain assessment tools is the fact that proxy raters and 
patients’ self-reported pain experience only demonstrate moderate correlation at the 
best. Labus et al. (2003) reviewed 29 studies, the majority of the samples in these 
studies (58.6%) suffered from chronic pain, acute (13.8%), post-surgical (6.9%), and 
mixed pain (20.7%), in order to explore the degree of association between patients’ 
self-reports of pain and observational pain ratings (Labus et al. 2003). The association 
was only moderate and they conclude in accordance with other studies by 
recommending to combine observation and self-report ratings (Keefe et al. 
2001;Labus et al. 2003). A study by Prkachin et al. (1994) where five observers 
(undergraduate students) watched videotapes of patients with shoulder pain indicated 
an equivalent mismatch between patients’ self-report and behavioural ratings by “pain 
judges”, and it was further emphasized that the judges underestimated pain and that 
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the less trained judges overlooked valuable information in the facial expressions 
(Prkachin et al. 1994). 
Divergences between behavioural ratings and self-reports are problematic, and in 
patients who are able to self-report, studies which compare observation and self-report 
have disclosed and highlighted insufficiencies in behavioural pain assessment. 
Consequently, observational methods of behaviour should only be used as stand-alone 
measures in patients where no other alternatives exist (Keefe et al. 2001). Behavioural 
pain assessment tools are intended to guide the proxy rater with regard to which 
behavioural clues that might indicate pain. On the other hand, behavioural pain clues 
like facial expressions, protection of sore areas and unexplained agitation should be 
well known to health care providers with some competence in pain. The question to 
remain is weather these tools can replace competence in pain and consequently have 
value in situation where other pain expertise lacks and if they can have a unique value 
in standardizing proxy rated pain scores. 
1.5.1 Behavioural pain assessment tools 
Although data on the performance of the different behavioural pain assessment tools 
are limited, a recent review rated 12 tools according to several quality criteria 
evaluating their psychometric aspects (Zwakhalen et al. 2006b). The tools could 
receive an overall judgement score from zero, denoting poor performance, to 20, 
indicating excellent performance with regard to issues of validity and reliability. Five 
English language tools received a review score of 10 or higher: the Abbey Scale 
(Abbey et al. 2004), the Pain Assessment for the Dementing Elderly (PADE) 
(Villanueva et al. 2003), the Pain Assessment in Advanced Dementia Scale 
(PAINAD) (Warden et al. 2003), the Pain Assessment Checklist for Seniors With 
Limited Ability to Communicate (PACSLAC) (Fuchs-Lacelle and Hadjistavropoulos 
2004), and the Doloplus-2 (Lefebvre-Chapiro 2001). All the tools cover facial 
expressions, abnormalities in body postures/movements like guarding sore areas, 
impaired movement and verbal expressions. The Abbey Scale, Doloplus-2, PADE and 
PACSLAC all include items on interpersonal communication, social life, participation 
in activities, and changes in daily routines. Looking at differences between the tools, 
the Abbey Scale and the PACSLAC include items on physiological changes 
(temperature and pulse (flushing or pallor). The Abbey Scale also assesses physical 
changes such as skin tears and pressure areas. The PADE includes a Visual Analogue 
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Scale for pain intensity and the PAINAD assesses breathing and consolability. The 
number of items ranges from 5 (PAINAD) to 60 (PACSLAC). All tools are 
constructed for administration by health care providers, but to our knowledge none of 
them claim any criteria with regard to the administrators’ competence. All tools 
include domains that may not exclusively be affected by pain. The review suggested 
that the Doloplus-2 and the PACSLAC were the most promising (Zwakhalen et al. 
2006b). All these tools are developed and tested in either nursing home residents, 
veterans or in patients at geriatric hospital wards. 
1.6 Psychophysiological assessment 
Methods for psychophysiological assessment of pain are in an early phase of 
development. Such assessments feature blood-flow based neuroimaging, tests of heart 
rate and blood pressure, skin conductance and measures of muscle tension with 
electromyographic recordings (Flor 2001). These assessments are complicated to 
conduct in daily clinical work, and at present it is not obvious how such measures can 
address pain as defined by IASP. The subjective experience cannot be properly 
assessed by today’s technology. Hence, psychophysiological measures are mainly 
developed for supplementary assessments to self-report in chronic non-malignant pain 
conditions. These measures need to be validated and calibrated for patients with 
advanced metastatic disease with major pathological findings. In some patients, 
psychophysiological results can be integrated as a part of a communicative treatment 
process teaching the patient how to cope with pain or as supplements in diagnostics in 
complex cases (Flor 2001). Such assessments are not a part of pain assessment in PC 
and will not be further discussed in this thesis. 
1.7 Psychometric properties of assessment tools 
Validity and reliability are cardinal properties of all assessment tools. An illustration 
of both is pistol shooting at a target. If a series of bullets is centred you have 
reliability, even though the hits can be outside the bull’s eye. Validity is when the hits 
are centred on the bull’s eye, the optimal is when all hits are centred indicating top 
validity and reliability. Tests have to be reliable to be valid. The validation of an 
assessment tool is the process of determining whether the tool really assesses what it 
is believed to assess and whether it is useful for the intended purpose (Fayers and 
Machin 2007). 
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Validity regards the tool’s ability to measure what it is supposed to measure. Validity 
is closely related to the operationalization of the phenomenon. To develop a valid pain 
assessment tool one needs to choose a proper definition of what pain is. This 
definition has to be operationalized into a measurable construct. Issues of validity 
contain a set of different methods for testing whether a measure has any systematic 
errors affecting its ability to measure the original construct. Construct, content, and 
criterion validity are all important aspects of the validity of assessment tools (Fayers 
and Machin 2007). All three cover the tool’s ability to measure the given phenomenon 
and that alone. 
Content validity is subjective and qualitative: does the instrument contain the 
appropriate items, in terms of relevance and breadth of coverage? All the relevant 
issues should be covered by items in the tool. When the assessment tool has a 
comprehensive coverage of the phenomenon that it is intended to assess, it will 
increase the tools specificity and sensitivity (Fayers and Machin 2007). This is 
important to disclose differences between groups of patients. If the tool lacks items on 
one aspect of the phenomenon it will obviously also lack the ability to differentiate 
patients who are different on those parts but equal on the assessed parts of the 
phenomenon. Tests of content validity include judgements by expert panels who 
evaluate the face validity of the test (Bland and Altman 2002); does the test cover 
what is known to be relevant aspects of the phenomenon, and does it contain aspects 
believed to be irrelevant. Studies on the content validity of pain assessment tools are 
scarce.
Criterion validity regards the comparison of the assessment tool against the true value 
or a value that is an accepted indication of it (Bland and Altman 2002). Pain is a 
subjective symptom and there is no access to the true value. Instead the patient’s self-
report of pain is regarded the “gold standard” and this is used as if it was the true 
value. Patients with cognitive impairments may be unable to self-report pain. The 
alternatives are then to compare the relevant assessment tool against values obtained 
from well-established pain assessment tools for this population, against in-depth 
interviews or observer’s assessments (Fayers and Machin 2007). Tests of criterion 
validity demand a reflexive model (Hellevik 1991), here illustrated by the theoretical 
model of pain with two operationalized sub-models; a pain score based on an expert’s 
clinical evaluation of the patient and a score from the Doloplus-2, a behavioural pain 
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assessment tool (Figure 2). Correlation between those two models indicates that they 
measure the same phenomenon. Often, one of the sub-models is an accepted valid 
measure of the phenomenon (in this case a clinical evaluation by an expert). When the 
new measure correlates with the criterion it has criterion validity. 
Figure 2: 
Pain
Expert’s pain 
score
Doloplus-2 score
Operationalized variablesTheoretical variable
Correlation
Figure 2 presents an indirect method for testing the criterion validity of the Doloplus-2. The 
assumption is that the expert’s pain score is a valid representation of the true pain value and that a 
high correlation between the expert and the Doloplus-2 indicates that the Doloplus-2 assesses pain. 
The criterion validity can also be described by its predictive validity which regards 
the ability of a measure to predict future events. An indication of predictive validity 
will be that a pain score is successively reduced with repeated measures after the 
administration of analgesics. 
Construct validity is assessed quantitatively, and consists of several sub concepts. The 
purpose is to examine whether the tool assesses the concept that it is intended to 
assess (Bland and Altman 2002;Fayers and Machin 2007). The first step is to form a 
hypothetical model of the phenomena in interest and the relationship between them. 
The second step is to test this model empirically. The construct validity may be 
satisfactory if the data supports the hypothesis. To establish construct validity is a 
thorough process and involves repeated testing. The aim is at best to collect data that 
support the fact that the tool really assesses the intended phenomenon (Fayers and 
Machin 2007). The analyses of construct validity are usually translated into looking 
for evidence that the items behave in the expected manner, given our hypothesized 
scale structure (the constructs)? Hence the construct validity has to do with within-
instrument correlations between items/items, scales/scales and items/scales. 
Comparison of known-groups is one way to assess construct validity. One expects 
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that the assessment tool should be sensitive towards known-group differences. 
Convergent validity is another aspect that regards the correlation between scales and 
items that assess what is believed to be related phenomena (Campbell and Fiske 
1959). The opposite is discriminant validity that regards the tools ability to 
discriminate between phenomena that are believed to be unrelated by finding low 
levels of correlation, both can be tested in a Multitrait-Multimethod matrix of 
intercorrelations among tests representing at least two traits, each measured by at least 
two methods (Campbell and Fiske 1959). Validity is found when tests of the same 
trait correlates higher than they do with measures of different traits. 
Reliability regards the random errors in a measure. The assessment tool’s reliability 
concerns its ability to produce reproducible and consistent results (Fayers and Machin 
2007). Reliability has a time aspect in test-retest situations and a person aspect in 
inter-rater reliability. Both kinds concern the test’s ability to produce consistent 
results independent of time and person. In pain assessment it is important that a tool 
produces the same results in the same person at each assessment, independently of the 
test situation and the administrator of the tool, as long as the pain level is unchanged. 
Reliability can be expressed by a correlation coefficient ranging from 0 (no) to 1 
(perfect). The Intra Class Correlation coefficient (ICC) is the most common method 
for assessing reliability with continuous data (Fayers and Machin 2000). A high ICC 
is produced when a large proportion of the total variance is related to the between 
patient variability. A coefficient above 0.70 is usually regarded as acceptable (Fayers 
and Machin 2000). Internal consistency is a central characteristic in multi-item scales. 
Cronbach’s alpha is a common measure for internal consistency. It is a function of the 
average correlation between the items in the scale and the number of items and it 
increases when either of this increases (Bland and Altman 1997;Fayers and Machin 
2000). Cronbach’s alpha is often used as a measure of reliability, but it is also closely 
related to construct validity in terms of the focus on inter-item relationship. It can be a 
valuable estimate when evaluating the usefulness of different items in a scale. If the 
removal of an item from a scale only results in a little decrease in the Cronbach’s 
alpha, the item can usually be removed from the scale. 
A challenge with the scales used in pain assessment is so-called floor and ceiling 
effects. This may be illustrated by clusters of assessment scores either at the bottom 
(floor) or at the top end (ceiling) of the scales. The phenomenon affects the scale’s 
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ability to discriminate between subjects that are believed to have different true scores. 
A ceiling effect may also occur with repeated measurement over time if pain 
increases. A patient, who initially rates pain intensity at 9 on a scale from 0 to 10, 
encounters trouble when the pain increases and the next true score would have been 
12, but the scale does not go beyond 10, thus creating a ceiling effect. Ceiling effects 
are most frequent in single item scales, however, a broader approach to ceiling effects 
that also applies to multidimensional tools, is addressed in theories about response 
shift (Schwartz and Sprangers 2000). In assessments of subjective health and quality 
of life, patients' frames of reference tend to shift according to current health status. 
That leads patients to adjust their expectation due to their current status. Anticipated 
decreases in assessed status due to worsening symptoms may fail to appear in the 
assessment scores. And effects of successful interventions may be invisible for 
assessment (status quo), because the patient, in the mean time, has reduced his 
tolerance for pain and thus reports identical pain scores as before the treatment. The 
response shift phenomenon can such bias longitudinal/repetitive pain assessments due 
to changes in patients' experience of pain over time due to coping and 
lowering/heightening of frames of reference (Schwartz and Sprangers 2000). 
1.8 International standardization 
There is no international standard for pain assessment neither in clinic nor in research. 
Instead of consensus there is an abundance of different tools in use. This prevents 
meta-analyses and the communication of assessment results within the research 
communities (Quigley 2002;Nicholson 2004). Thus there is a need to develop an 
international standard for pain classification and assessment. A standardization of 
pain assessments is likely to improve clinicians’ and researchers’ interpretations of 
pain scores and it may allow for a much needed opportunity for comparing results 
from different research projects. Today researchers conduct almost identical pain 
research with slightly different outcome measures. It will be much more efficient to 
coordinate pain research if one can achieve a standardization of pain measures. New 
pain tools with improved psychometric properties and feasibility may accelerate the 
will among researchers to reach standardization. 
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2. Material and methods 
2.1 Setting 
This thesis is based on studies performed within the Pain and Palliation Research 
Group at NTNU / St. Olav’s University Hospital, Trondheim, Norway. The group is 
multidisciplinary with (in alphabetic order) nurses, physicians, physiologists, 
physiotherapists, psychologists and statisticians. The group enjoys close collaboration 
with other European palliative care researchers, mostly through the EAPC Research 
Network (www.eapcnet.org). One of several objectives for the group is to contribute 
to improved pain assessment through systematic research. 
2.2 Patient cohorts 
This thesis consists of four studies in principally two patient populations; cancer 
patients and demented nursing home residents. The cancer patients were recruited 
from the Department of Oncology and the Palliative Care Unit at St. Olav’s 
University Hospital while the demented patients came from nursing homes in the 
Trondheim region and from the Geriatric Ward at St. Olav’s University Hospital. In 
addition, patients with noncancer chronic pain (NCCP) from the National Centre of 
Expertise for Pain and Complex Disorders at St. Olav’s University Hospital were 
included as a comparison group for cancer pain patients. 
Table 1: Overview of study samples 
Patient samples N Sex (% men) Age median Study
Cancer
NCCP
Demented nursing home 
Demented nursing home/ 
Geriatric ward 
300
286
59
73
55
34
20
26
63
44
82
85
II
II
III
IV
2.3 Study designs 
Study I combined a systematic literature review with an expert group evaluation of 
the relevance of the pain dimensions found. Two literature searches were conducted 
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in order to find pain assessment tools. A systematic search was conducted on the 
search terms pain assessment and pain measurement. To include a tool from the 
systematic search the title or abstract should describe: a) A self-report method used for 
pain assessment or the name of an assessment tool explicitly used for self-report of pain 
and b) a sample with adult advanced cancer patients receiving palliative care. The search 
was a computerized literature search in Pubmed (MEDLINE), Cancerlit, PsychInfo, 
and Cinahl. The Cochrane Library review group for Pain, Palliative & Supportive 
Care was also consulted and a book search was conducted in the Norwegian library 
database BIBSYS (international). The search was restricted to publications in English. 
Case reports, editorials, letters, and commentaries were excluded. The systematic search 
was supplemented by a broader ad-hoc search in MEDLINE for pain assessment tools 
used in other populations (without criterion b in the systematic search). Because of the 
vast amount of publications on pain assessment in general, the following MEDLINE 
limitation options were deployed: English language, abstracts available, humans, all 
adult (19 years or above), and full text. After the literature search, all pain assessment 
tools and the papers describing the construction of the tools were examined for 
information about the content expressed by their pain dimensions and the items 
covering them. In line with the study objectives, an international expert panel was 
established. The experts were instructed to rank the different pain dimensions, which 
were found in the literature, according to their relevance for pain assessment in PC. 
The items in the identified tools were allocated to appropriate dimensions by the first 
author and then this assignment was reviewed by the experts. 
This study was the first step of the ”Palliative Assessment Tool - Computerized” 
(PAT-C) project, which aimed at developing a computer-based tool for assessment of 
symptoms and functioning in PC patients (PAT-C at EAPC web 2006). To be able to 
select appropriate pain dimensions and items of relevance for a PAT-C Pain 
Assessment Tool, there was a need to define which dimensions, and the 
operationalization of them into items, that fall within the scope of pain assessment in 
PC patients. The European Organisation for Research and Treatment of Cancer 
(EORTC) describes the generation of new QOL issues and symptom assessment tools 
in three steps (Sprangers et al. 1998). The first step involves literature searches where 
the aims are to review the existing knowledge on the field of interest and to derive 
potentially new relevant and improved issues. The second step involves experts on the 
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field who should be instructed to provide feedback on the appropriateness of the 
content and the breadth of coverage. In step three the patients are consulted, usually in 
a pilot test of the new assessment tool. Study I covers the two first steps with 
literature searches and expert panel. 
The patients with cancer and NCCP took part in Study II (study objective 2) where 
the aim was to explore how pain’s interference with functions is reported through the 
BPI. All patients completed the BPI-sf and the European Organisation for Research 
and Treatment of Cancer’s quality of life questionnaire (EORTC QLQ-C30) 
(Aaronson et al. 1993) which is a widely used HRQOL questionnaire with well 
documented reliability and validity in patients with cancer and recently validated in 
patients with NCCP (Aaronson et al. 1993;Hjermstad et al. 1995;Wisloff et al. 
1996;Fredheim et al. 2007). Background information on sex, age and diagnoses\pain 
conditions was collected from all patients. A research nurse browsed through the 
journals of all in-patients at the cancer department in order to find eligible candidates 
for study participation. The patients were usually approached in their room and asked 
to complete the questionnaires on the same day. The EORTC QLQ-C30 and the BPI 
were presented as a one questionnaire package. This material was originally collected 
for the Norwegian validation study of the BPI-sf and for a pharmacological study on 
morphine (Klepstad et al. 2002;Klepstad et al. 2003), but the data was made available 
for the present study. The patients with NCCP were consecutively recruited by the 
staff at the pain clinic and they received the same questionnaire package by mail. 
Their responses were mailed back before their first consultation at the pain clinic. 
Study III and IV include institutionalized patients with cognitive impairment from a 
geriatric hospital ward and from five different nursing homes. These patients were 
selected as appropriate for testing the feasibility and validity of the Doloplus-2 (study 
objective 3). All patients were cognitively impaired and evaluated as unable to self-
report pain by the nursing home personnel. Each patient was examined by an expert in 
pain assessment and treatment, who rated pain on a numerical rating scale (See 
Appendix). These ratings were used as pain criterion. All administrators were trained 
in Doloplus-2 assessment according to the guidelines provided by the French 
developers (Appendix). Cognitive function was assessed by the Mini Mental State 
Examination (MMSE), and the ability to perform activities of daily living was 
evaluated with the Barthel Index (these tools are described in chapter 2.4). 
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In study III the Doloplus-2 was translated into Norwegian according to international 
guidelines (Cull et al. 1998). The criterion validity of the Doloplus-2 was tested by 
comparing Doloplus-2 scores against the pain experts’ proxy-pain ratings on a NRS-
11. The Doloplus-2 was administered by nurses and nurse assistants who were 
accompanied by two final year medical students. The administrators completed a 
debriefing questionnaire about their experiences with the tool and its translation 
(Appendix).
In study IV further tests of the criterion validity of the Doloplus-2 was performed with 
a similar design. The Doloplus-2 was administered by the attending nurse. In 16 
patients the Doloplus-2 was independently administered by two nurses, blinded to 
each other, in order to evaluate the inter-rater reliability. Similarly were 15 patients 
evaluated by the regular expert in addition to two independent geriatricians (all 
blinded) in order to evaluate the validity of the pain criterion. 
Both the cancer and the nursing home groups in these three studies consist of patients 
where life prolonging and/or palliation were the major aims for treatment and care. 
2.4 Assessment tools 
The assessment tools that were used in the studies are presented in the Appendix. 
Table 2: Overview of the assessment tools that were used in each study 
Tool Study(ies)
Barthel index
Brief pain inventory-sf 
Doloplus-2
EORTC QLQ-C30 
Karnofsky performance status 
Numerical rating scale 
Mini mental status exam 
III & IV 
II
III & IV 
II
II
III & IV 
II, III & IV 
The following assessment tools were used in the studies: 
Self-report tools (alphabetically) 
35
2.4.1 Brief Pain Inventory short form (BPI) 
The BPI-sf has mainly replaced the full version in use. BPI refers from here to the 
short version. The BPI is a self-report pain assessment tool and the patient is 
instructed to report pain as intensity and as interference with seven different functions 
(Cleeland 1991;Pain Research Group at MD Anderson Cancer Centre 2006b). The 
intensity scale contains four items measuring worst, least and average pain intensity 
(usually during the past 24 hours or past week) and intensity now. The interference 
scale includes seven items which assess pain’s interference with general activity, 
mood, walking ability, normal work, relations with other persons, sleep, and 
enjoyment of life. The response alternatives are all numerical rating scales running 
from 0-10 (NRS-11). The intensity items are bounded by the words “no pain” and 
“pain as bad as you can imagine” and the interference items with “does not interfere” 
and “interferes completely”. In addition, the patient reports pain localization on a 
body map drawing and details on their current pain medication and its effectiveness. 
The BPI has been validated as a measure for cancer pain in many cultures and 
languages (Caraceni et al. 1996;Wang et al. 1996;Uki et al. 1998;Ger et al. 
1999;Saxena et al. 1999;Radbruch et al. 1999;Mystakidou et al. 2001;Klepstad et al. 
2002;Badia et al. 2003;Yun et al. 2004) and it is recommended as a cancer pain 
assessment tool for palliative care patients by the Expert Working Group of the 
European Association of Palliative Care (Caraceni et al. 2002). The Norwegian 
translation has demonstrated satisfactory psychometric properties in advanced cancer 
patients (Klepstad et al. 2002). 
2.4.2 European organisation for research and treatment of cancer’s core 
quality of life questionnaire (EORTC QLQ-C30) 
The EORTC QLQ C-30 consists of 30 items for patients’ self-report of functions, 
symptoms and quality of life (Aaronson et al. 1993). Norm data for the EORTC QLQ 
C-30 have been published for the Norwegian general population and the scale has 
been examined for test\retest reliability which was satisfactory in a Norwegian cancer 
population (Hjermstad et al. 1995;Hjermstad et al. 1998). Response categories are 
verbal rating scales running from 1= not at all to 4 very much for the items on 
symptoms and functions and from 1= very poor to 7= excellent on the QOL items. 
Twenty-four items are clustered into multi-item scales; Physical, Role, Cognitive, 
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Emotional, and Social; three symptom scales: Fatigue, Pain, and Nausea and 
vomiting; and a global health and QOL scale. The last six are single items covering: 
dyspnoea, sleep, appetite, constipation, diarrhoea, and the financial impact of the 
disease and treatment. The two pain items address pain intensity and pain’s 
interference with daily activities. 
For the functioning scales and the global health and QOL scale, a high score 
represents good functioning. In the symptom scales a high score represents a high 
level of symptoms. All scores are transformed into a 0 to 100 scale after the following 
procedure, score = : 
Function scales:  100 – (mean score -1)* 100/range 
Symptom scales: (mean score -1)* 100/range 
Global QOL scale: (mean score -1)* 100/range 
Single items: (mean score -1)* 100/range 
2.4.3 Numerical rating scale (NRS) for pain 
This unidimensional single-item scale was used for proxy ratings of pain by the pain 
experts in studies III and IV. These ratings were used as pain criterion. Each patient 
was rated by one expert. The experts based their judgement upon information in the 
medical record, information from the nurse responsible for the patient and the 
patient’s primary contact (usually an enrolled nurse), information from the patient (if 
possible) and a clinical examination. The experts were instructed to rate the intensity 
of each patient’s pain on a NRS-11 from zero (no pain) to ten (worst imaginable 
pain). Each patient was rated by the expert for pain in movement and rest separately. 
The scale is further described in the previous chapter 1.4.1 Unidimensional pain 
assessment.
Observer rated tools (alphabetically)
2.4.4 Barthel Index 
Ability to perform activities of daily living (ADL) was evaluated by the original 10-
items Barthel Index (Mahoney and Barthel 1965) in studies III and IV. This tool 
describes the ability to perform ADL on a scale from 0 - 20. The items cover the 
activities of controlling the bladder and bowels, maintaining personal toilet, 
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bathing/showering, feeding, moving from chair to bed and up again, getting on and 
off the toilet, indoor mobility, dressing and ascending/descending stairs. The ratings 
are indented to suggest how much assistance the patient needs. Barthel index scores 
from 20 to 15 indicate independence to mildly disabled ADL function, 14 - 10 
indicate moderately disabled, while a score of 9 - 0 indicates that the patient is 
severely disabled to very severely disabled (Wade and Hewer 1987). The Barthel 
Index was scored by a nurse who had worked closely with and knew the patients and 
who was trained in using the Barthel Index. 
2.4.5 The Doloplus-2 
The Doloplus-2 tool consists of one page with all ten items, one page with a lexicon 
describing the different items, and finally there is a user guide available. The 
Doloplus-2 should be used by a trained health care worker, familiar with the patient’s 
habits and regular condition, who observes the patient’s behaviour and rates pain 
according to the degree of presence of certain behavioural clues (Lefebvre-Chapiro 
2001). The Doloplus-2 includes three hypothesized domains; somatic, psychomotoric 
and psychosocial. The somatic domain consists of five items, the psychomotoric 
domain has two items, and the psychosocial domain has three items. Each item has 
four response alternatives with a scoring range of 0 to 3. A score of 0 indicates that 
the patient behaves normal on the given item, 1 signifies some pain related behaviour, 
2 more pain behaviour, and a score of 3 means that the patient demonstrates high 
levels of pain-related behaviour. The possible total score ranges from 0 to 30. Based 
on their clinical judgement, the developers of the French version recommend that a 
total score of 5 points or more should be regarded as a sign of pain that may require 
treatment with analgesics (Doloplus-2 Instructions for Use, Appendix). However, this 
cut-off has not been validated and the tool developers point out that the Doloplus-2 
does not rule out pain as an option even below a score of five. The Doloplus-2 
Instructions for Use also informs users only to rate those items found suitable for each 
patient.
2.4.6 Karnofsky Performance Status (KPS) 
Performance status was rated with the Karnofsky Performance Status (Karnofsky and 
Burchenal 1949;Patrick and Deyo 1989) in the cancer patients included in Study II by 
one of the investigators. The KPS has demonstrated good construct and predictive 
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validity and good inter-rater reliability as a global indicator of the functional status of 
cancer patients (Yates et al. 1980). The KPS is a numerical rating scale that measures 
physical function, general health status and medical requirements. It contains 11 
categories and a score of 0% means death while 100% indicates normal performance, 
no complaints, no evidence of disease. 
2.4.7 Mini Mental State Examination (MMSE) 
Cognitive function was assessed by the Mini Mental State Examination (MMSE) 
(Folstein et al. 1975;Folstein et al. 1984) in studies II, III and IV. The MMSE contains 
11 items and covers the person’s orientation towards time and place, motor skills, 
recall ability, short-term memory, and arithmetic ability. It rates the level of cognitive 
function on a scale from 0 - 30. Patients with scores from 30 - 21 are regarded as 
normal in cognitive function to mildly cognitively impaired, scores from 20 - 11 
denote moderately cognitive impairment, while patients scoring 10 - 0 are classified 
as severely cognitively impaired (Perneczky et al. 2006). The MMSE is a screening 
test for cognitive loss and cannot be used to diagnose dementia (Folstein et al. 1975). 
2.5 Statistical analyses 
The results are presented as means for normal distributed variables or medians for 
non-parametric variables while the distribution of the data is generally presented 
using standard deviation, 95% confidence intervals or range as appropriate or 
according to the different directions given by the journals. 
In study II, 300 patients with cancer and 286 patients with NCCP completed the BPI 
and the EORTC QLQ-C30. The pain interference items were indexed into total 
interference, interference with physical, and interference with psychological 
functions. A number of different regression analyses were used in order to explore the 
relationships between patient groups (cancer and NCCP), levels of pain intensity, age, 
sex, and different dimensions of HRQOL on pain’s interference with functions. The 
dependent variables were pain interference on physical and on psychological 
functions in two separate analyses. Independent variables were pain intensity and 
patient group, and a possible interaction between them. For statistical testing 
purposes, in order to account for significant non-linear relationships, we used 
fractional polynomial regression (Royston and Altman 1994;Royston and Sauerbrei 
2004). Using fractional polynomials, it is possible to model nonlinear relationships 
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with a low number of terms (usually one or two per covariate) in the regression 
model. Polynomial regression, on the other hand, typically requires more terms and 
also approximates data sets less well, especially at the end values of the scales. 
Possible effects on the results by adjusting for age or sex, as well as for all EORTC 
QLQ-C30 scales, were studied by entering these one at a time in the regression 
models. Model selection in fractional polynomial regression was performed as 
described by Royston and Altman (1994). This is an adapted stepwise forward 
selection procedure using the likelihood ratio (LR) statistic. Significance testing in the 
selected fractional polynomial regression model was carried out using Student's t 
statistic. Two-sided P-values <0.05 were considered significant. 
In study III, the criterion validity of the Doloplus-2 scores was estimated by 
comparing it against the pain experts’ pain ratings on a NRS-11 with a univariate 
regression analysis. This ability of the Doloplus-2 to explain the expert’s ratings was 
expressed through the squared regression coefficient R2. Univariate regression 
analyses were also performed to explore how each item could explain the expert score 
alone, and a step-wise (forward) regression analysis produced the best model 
(sequence) of items for explaining the expert score. The Doloplus-2 administrators 
completed a debriefing questionnaire. 
In study IV, univariate regression analyses were used to estimate the ability of the 
Doloplus-2 to explain the expert’s ratings (only one expert in study IV). This ability 
was expressed through the squared regression coefficient R2. The contribution of each 
item in explaining the expert score was estimated with entering one item at the time in 
a univariate regression analysis to avoid problems of colinearity. The inter-rater 
reliability of the Doloplus-2 was evaluated in 16 patients by comparing the ratings of 
two independent Doloplus-2 administrators with intra-class correlation analysis. The 
performance of the pain expert was evaluated by comparing his pain ratings with the 
equivalent ratings of two geriatricians in 15 patients, with intra-class correlation 
analysis. Both intra-class correlation analyses were significance tested with F-tests. 
Statistical analyses were performed with the SPSS statistical software versions 11, 12, 
and 14 (SPSS inc., Chicago, Il, USA) and Stata version 9 (StataCorp, College Station, 
Texas, USA). 
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2.6 Ethics 
The Regional Committee for Medical research Ethics in Central Norway (REK) 
approved the protocols for study II, III and IV. A majority of the participating patients 
in these studies were in a vulnerable situation with advanced disease and/or reduced 
ability to give informed consent. Research on such patients puts an extra obligation on 
the researchers in evaluating the ethical aspects of the research. It is important to give 
the patients relevant and understandable information about the study and any 
participation should be totally voluntary. 
The cancer patients in study II were informed prior to the data collection and gave 
informed consent for voluntary participation. The patients with NCCP in study II 
completed the BPI and the EORTC QLQ-C30 in front of their consultancy at the 
National Centre of Expertise for Pain and Complex Disorders at St. Olav’s University 
Hospital of Trondheim. These data were made available to us as a part of evaluating 
the clinical procedures for pain assessment in the clinic. All data were made 
anonymous before the researchers got them for analyses. The procedure was 
suggested and approved by REK. The cancer patients and the patients with NCCP 
completed questionnaires (BPI and EORTC QLQ-C30) that also are parts of the 
regular clinical routine, thereby minimalizing the patient burden. 
According to the Oviedo Convention by the Council of Europe on human rights and 
biomedicine, research on patients unable to give informed consent should only be 
performed when the results of the research have the potential to produce real and 
direct benefit to his or her health, research of comparable effectiveness cannot be 
carried out on individuals capable of giving consent and when the person do not 
object to participate (Council of Europe 1997). A close relative of each patient in 
Study III and IV was informed about the study and patients were not to be included if 
the relative refused (no one did). Participation in these studies was considered to be of 
very little burden and risk to the patients who could also benefit directly from the pain 
consultations that came with the participation. All patient identifiable data were made 
anonymous at the institutions before the researchers got them. 
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3. Results, summary of papers 
Paper I: 
Pain assessment tools - is the content appropriate for use in palliative care? 
The main objective of this study was to evaluate the importance of different pain 
dimensions for pain assessment in PC. 
A total of 402 different citations were retrieved through the systematic literature
search for self-report methods used for pain assessment in a sample with adult 
advanced cancer patients receiving PC. 
Examinations of the titles and the abstracts identified 48 papers that met our inclusion 
criteria. Sixteen different tools for pain assessment used in PC studies were retrieved. 
The ad-hoc search, to identify self–report based assessment tools for adults in all 
populations, resulted in a total of 18021 hits. When this search was limited according 
to the search criteria, the numbers were reduced to 1391. 
The literature searches generated a total of 80 different assessment tools containing at 
least one pain item. The tools contained 1011 pain items in total. Examination of the 
searches identified 11 different pain dimensions. The dimensions for “pain relief 
(exacerbating/relieving factors)” and “benefits from treatment” were collapsed into 
one dimension named treatment and exacerbating/relieving factors after the initial 
suggestion of one expert and the approval by the others. The rationale was to make 
one dimension that included non-treatment and treatment factors (medical and non-
medical) that influenced upon the pain. The number of pain dimensions was thus 
reduced from 11 to 10. The expert panel evaluated the 10 dimensions for their 
relevance for pain assessment in PC research and clinic in the following order: Pain 
intensity, Temporal patterns, Treatment and exacerbating / relieving factors, Pain 
location, Pain interference, Pain quality, Pain affect, Pain duration, Pain beliefs, Pain 
history. The five first dimensions were evaluated as important by all experts, while 
the rest of the dimensions were omitted by one or more experts. The three most 
frequently assessed dimensions in the retrieved pain assessment tools were: intensity 
in 55 tools, interference in 37 and beliefs in 22, while duration and history were 
assessed in six and four tools respectively. 
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Three of the reviewed tools covered all of the five highest ranked dimensions: the 
Aberdeen Low Back Pain Scale (AB) the World Health Organization Quality of Life 
Assessment Tool – Pain Module (WHQOL-Pain) and the Pain Assessment 
Questionnaire for a patient with advanced disease (PAQ). The PAQ and the WHQOL-
Pain included several dimensions in addition to the five which were recommended by 
the experts and is consequently more burdensome to complete. The AB is only suited 
for back-pain assessment. None of these assessment tools from the literature searches 
cover the five most recommended dimensions satisfactorily. 
Most items were related to interference (231, ranked in fifth place), and intensity 
(138, ranked in first place). Temporal pattern, ranked as the second most important 
dimension, was covered by 29 items only. The expert panel allude that many tools 
include dimensions and items of limited relevance for patients in PC. Hence, the 
content validity of the existing tools is questionable in PC. 
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Paper II: 
The Brief Pain Inventory: Pain's interference with functions is different in 
cancer pain compared with noncancer chronic pain. 
The aim of the study was to explore how patients in PC report pain’s interference with 
functions as measured by the BPI. 
We hypothesized that cancer patients would report higher pain interference on 
physical functions than NCCP patients due to their advanced disease. The cancer 
patients reported higher values of physical interference than NCCP patients with the 
same level of pain intensity (p<0.001). NCCP patients reported higher values of 
psychological interference than cancer patients (p= 0.023). For total interference these 
effects eliminated each other. When adjusting for the EORTC QLQ-C30 subscale for 
physical function the group effect became insignificant for physical interference 
(p=0.30), while the results still remained significant when adjusting for age, sex, and 
the EORTC QLQ-C30 subscales. The results from the EORTC QLQ-C30 
demonstrated a lower level of physical functioning in the cancer patients (physical 
function mean score: Cancer =38, NCCP = 51). Adjusting for the QLQ-C30 subscale 
for physical function eliminated the group difference on pain interference with 
physical functions, denoting that level of physical functioning is more important for 
reports of pain’s interference with physical functioning than level of pain and group 
identification. The NCCP patients have a linear relationship between intensity and 
pain’s interference with physical function while the relationship reaches a ceiling 
effect already at a pain intensity of four in the cancer patients. This is caused by 
several cancer patients reporting very high pain interference and no pain to moderate 
pain.
The patients with NCCP reported more pain’s interference with psychological 
function than the cancer patients and these results were also found in the EORTC 
QLQ-C30 data which indicate that the NCCP patients demonstrate poorer 
psychological functioning. The NCCP patients report lower emotional and social 
functioning than the cancer patients, but most significant is a substantially higher 
level of insomnia reported by patients with NCCP (Insomnia mean score: Cancer = 
35, NCCP = 66). 
The results indicate that the patients are unable to report isolated pain’s interference 
using the BPI. The level of physical functioning is more important for reports of 
45
pain’s interference on physical functioning than level of pain and patient group. 
Patients’ diagnoses have to be taken into account when interpreting assessment results 
of pain’s interference with functions.
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Paper III:
The Norwegian Doloplus-2, a tool for behavioural pain assessment: translation 
and pilot-validation in nursing home patients with cognitive impairment. 
The present pilot study aimed at translating the Doloplus-2 into Norwegian and 
testing its criterion validity and clinical feasibility. 
The Doloplus-2 was translated according to international guidelines provided by the 
EORTC. The final translation was spread in the study group and consensus was 
reached. According to contextual differences the backward translations differed a bit, 
but the content was similar. The Doloplus-2 administrators fully approved the final 
translation of the tool. 
Fifty-nine patients with a primary diagnosis of dementia were recruited, of whom 47 
were women. Median age was 82 years. Barthel index scores had a median of 15. The 
MMSE scores had a median of 9.
The mean pain expert score (NRS-11, pain-in-movement and pain-at-rest averaged) 
was 1.3 (SD= 1.6). Thirty four patients were rated with positive pain scores by the 
expert and 25 were rated with zero, as pain free. Twenty-nine patients had a Doloplus-
2 score 5, signifying pain possibly requiring treatment according to the 
recommended Doloplus-2 cut-off score guideline (Appendix). 
Among the patients that the experts rated as pain free, six had a Doloplus-2 score of 
zero and 19 had scores <5, leaving five false positives. Of the 59 cases, the Doloplus-
2 produced false negatives at ten occasions. A false negative occurs when the 
Doloplus-2 score is below the defined cut off point of five in the same case as the 
expert rated above zero (NRS-11). A univariate regression analysis was performed to 
explore how well the Doloplus-2 could explain the experts’ pain scores. The 
unstandardized residuals had a standard deviation of 1.02. The Doloplus-2 explained 
62% (R-square) of the pain distribution. 
Univariate regression analyses were performed with each item against the expert 
score variable (in order to avoid colinearity). The results in Figure 3 show how much 
variance each item explains in the expert score independent of the other items in the 
Doloplus-2.
47
1 2 3 4 5 6 7 8 9 10
Doloplus-2 items
0%
10%
20%
30%
40%
50%
Ex
pe
rt
 s
co
re
, e
xp
la
in
ed
 in
 %
 (R
-S
qu
ar
e)
C
om
m
un
ic
at
io
n
So
ci
al
 li
fe
Pr
ob
le
m
s 
of
 b
eh
av
io
ur
So
m
at
ic
 C
om
pl
ai
nt
s
Pr
ot
ec
tiv
e 
bo
dy
 p
os
tu
re
s 
ad
op
te
d 
at
 re
st
Pr
ot
ec
tio
n 
of
 s
or
e 
ar
ea
s
Ex
pr
es
si
on
Sl
ee
p 
pa
tte
rn
W
as
hi
ng
 &
/o
r d
re
ss
in
g
M
ob
ili
ty
Figure 3: Item contribution
A stepwise (forward) regression analysis demonstrated that Facial expressions
explained 48% (R-squared=.48) of the expert score alone. The analysis then included 
the items for protective body postures adopted at rest, communication, and somatic 
complaints as the items that consecutively could explain most of the remaining 
unexplained variance. Together they explained 68% of the total variability. 
The debriefing of the administrators disclosed that Doloplus-2 was helpful in 
detecting and assessing pain and it was easy to administer. The administrators 
reported that the items for psychosocial reactions should be cautiously scored as many 
patients have abnormal social reactions as a result of their dementia and not as a result 
of pain. It is therefore important to know the patient’s habits and regular behavioural 
patterns before scoring such behaviour as pain related. 
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Paper IV: 
Doloplus-2, a valid tool for observational pain assessment? 
The main objective of the present study was to test the criterion validity of the 
Doloplus-2.
A total of 73 patients were included from three different sites. The mean age of the 
sample was 84 years, and 74% were female. The median MMSE score was 10. The 
Barthel Index scores had a median value of 9.
The pain expert rated 47 patients as in pain, and 26 were rated as without pain. The 
mean pain expert score for pain-in-movement (NRS-11) was 1.5 (SD= 1.5). The inter-
rater reliability was estimated as the association between the pain expert’s ratings and 
two geriatricians’ ratings of the same patients (N=15) with an intra-class correlation 
of 0.74 with a 95% confidence interval from 0.5 to 0.89.
The mean Doloplus-2 score was 7.47 (SD=5.08) with a range from 0-22. Five patients 
received a Doloplus-2 score of zero. Among these, three were also rated as not in pain 
by the expert, while the other two received a score of zero at rest and two in 
movement. 
The regression analysis of the Doloplus-2 scores against the expert scores produced 
an R2 of 0.023, implying no criterion validity of the Doloplus-2 in this data set. The 
inter-rater reliability between the Doloplus-2 administrators assessed by the intra-
class coefficient was 0.77, with a 95% confidence interval of 0.47 - 0.92.
To explore the data more closely we analysed each study site separately. No 
significant results were obtained while looking at the complete data from the three 
sites; however, an association was found between the pain expert and the geriatric 
expert nurse (GN, the most competent administrator) who administered the Doloplus-
2 in 16 patients in the Section of Geriatrics, with an R2 of 0.54. Univariate regression 
analyses of the different Doloplus-2 items (full sample) showed small but significant 
relationships between the Doloplus-2 item for protective body postures at rest and the 
expert’s pain-in-movement score (R2=0.12, p=0.003) and for the Doloplus-2 item 
pain complaints and the expert’s pain-at-rest score (R2=0.13, p= 0.002). The 
Doloplus-2 identified a high number of false positive pain cases according to our pain 
criterion. A combination of more than one pain expert, other behavioral pain 
assessment tools, a verbal rating scale for self-report of present pain intensity and test-
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treatment with analgesics could constitute a comprehensive and promising pain 
criterion in future studies. 
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4. Discussion 
This thesis has aimed to establish some recommendations for valid and 
comprehensive pain assessment in all patients in PC - both for those who are able to 
self-report pain, and for those who are not able to. Our results indicate that the 
recommended tools for both self-report and behavioural pain assessment have short-
comings and questions are raised with regard to the validity of both the BPI pain 
interference dimension and the Doloplus-2. A panel of PC field experts gave 
recommendations on the content for future self-report based pain assessment tools. In 
behavioural pain assessment there is a need for further testing of the available tools 
for use in patients with cognitive failure and pain. 
The validity of our results depends on the design of our studies and on the inclusion of 
subjects. Validity of studies can be divided into internal and external validity (Juni et 
al. 2001). Internal validity regards whether the design of the study is appropriate for 
providing evidence about the given topic, is systematic errors minimised? External 
validity refers to whether one can make generalisations from the results to the general 
population at stake. Are the results valid for the population which the subjects are part 
of and maybe also for other similar populations than those in the studies? The 
limitations within the studies and the implications from the results will be discussed. 
The following discussion is divided into two parts, one for self-report and one for 
behavioural assessment. 
4.1 Pain assessment by self-report 
4.1.1 Study I 
In Study I we wanted to evaluate the appropriateness of the content of pain 
assessment tools for use in PC. Study I builds on and follows a well accepted EORTC 
guideline for establishing new standards for symptom assessment, by combining 
literature searches and panels of field experts (Sprangers et al. 1998). However, some 
limitations should be taken into account. As described in the paper, the area of pain 
measurement is huge and it was impossible to make a complete systematic search 
within the limits of the study. The systematic search, that was restricted to studies in 
PC populations, was therefore accompanied by a limited ad-hoc search for all pain 
assessment tools. This resulted in 80 assessment tools that included at least one pain 
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item. We are confident that this strategy revealed enough tools for pain assessment to 
produce a comprehensive description of the pain assessment tools in use today. The 
expert panel consisted of six experienced pain and PC specialists from five European 
countries, all members of the EAPC Research Network. The expert panel was 
structured by a Delphi method process. The aim of Delphi methods is to elicit and 
develop individual responses to the questions. Communication in the expert group 
was anonymous, in the sense that all feedback from the members of the expert panel 
was sent to the coordinator who then structured the different experts’ views and sent it 
back to the whole group without identification of individual contributions. The 
advantage of such a method is that social interaction between the members of the 
panel is minimised in order to receive all members’ individual views. Of the experts, 
five were male and one was female. One could have wished for a more even 
distribution between men and females. All the experts were physicians. In opposition 
to tools developed for cancer pain, the tools developed for complicated cases of 
NCCP have more focus on pain affect and quality and these tools are often developed 
by non-physicians e.g psychologists (Paper I). The constructor of the MPQ is also a 
psychologist and pays great focus to pain quality. The expert panel acknowledged the 
importance of the pain quality dimension, but it was expressed that this is more 
important in pain diagnostics and not for monitoring pain treatment in patients with 
advanced disease, a view supported by the EAPC’s previous publication with 
recommendations for pain assessment (Caraceni et al. 2002). During the review 
process nurses, psychologists and physiotherapists have been invited to comment on 
the recommendation from the expert panel, and all have approved these results. The 
rationale behind this choice of experts was that we wanted a highly competent 
statement with relevance for both clinic and research. Consequently, we invited 
leading capacities in the field. The panel could have been strengthened by additional 
participants, presumably also from outside Europe. 
Another limitation of the study is the lack of involvement of patients themselves in 
the process both to identify pain domains important/relevant to them and to 
select/review pain items to be used in the assessment. The patients could have been 
involved in this first process, but as our primary aim was to improve pain treatment 
we found it most appropriate to ask the physicians to tell us what information they 
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need from the pain assessment in order to provide optimal treatment. The choice of 
skipping the patients’ perspective at this point limits the results. 
As described, our study protocol followed the EORTC guideline for developing new 
assessment tools and as a next step in our development of a new pain assessment tool 
we did involve patients. The five expert-recommended dimensions were 
operationalized with items that we retrieved form the literature search in Study I. 
These items were also evaluated by the expert panel and assigned to what they 
perceived were the appropriate dimensions. A questionnaire with 58 items on the five 
dimensions was constructed and administered to seven cancer patients from the 
palliative medicine unit and 14 NCCP patients from the pain centre (spring 2004). 
They completed this questionnaire before they were interviewed with regard to their 
assessment experience with the EORTC debriefing guide (Cull et al. 1998). A main 
finding was that especially the cancer patients found it difficult to reply to items about 
pain interference. It may be speculated whether the pain interference dimensions 
would have reached the top five if we had taken the patient perspective into account 
in the first place and this reservation towards the assessment of pain interference 
inspired us to perform study II. 
4.1.2 Study II 
Through the literature review in Study I it was clear that the BPI could be complicated 
to understand and burdensome to complete for patients in PC. Additionally, our 
experience from the debriefing of the patients’ responses to the 58-items 
questionnaire and our clinical experience in the research group had taught us that the 
patients could find it difficult to respond to the items on pain’s interference with 
functions.
In study II we wanted to explore the construct validity of the pain’s interference with 
functions assessments in the BPI in PC patients. 
Some factors may have influenced the validity of our results. We chose the BPI- 
average pain intensity item as the pain intensity criterion. In our opinion this item is 
better suited as criterion than worst and least pain intensity, since these items are 
more concerned with floor and ceiling effects. Also, it is reasonable that the pain 
experienced most of the time is more important for pain’s interference than short 
periods with least/worst pain intensities. A test was performed with the pain worst
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item instead of the item for average pain intensity and the results were similar. We 
could have calculated the pain intensity index (summing or averaging the four 
intensity items), but the amount of missing items would have increased further and we 
found it more appropriate to use the average pain item which emphasizes the patient’s 
subjective averaged experience of pain in contrast to calculating an average index 
score.
We chose to split the pain’s interference with functions index into one dimension for 
physical and one for psychological functions in accordance with the factor structure 
that was demonstrated in the Norwegian validation study of the BPI (Klepstad et al. 
2002). The cancer patients report higher levels of pain’s interference with physical 
functions, while patients with NCCP report higher interference with psychological 
functions. The value of using separate interference scales for psychological and 
physical functions was hereby manifested as the group differences were invisible in 
the total interference score. 
There was a gap of five years between the data collections in the two populations. For 
the cancer patient population at St. Olav’s University Hospital there have been no 
major changes in treatment policies during the interval between the data collections. 
Therefore we do not believe this time frame has introduced any bias in the data 
analyses. The mode of administration differed between the two populations. The 
cancer patients completed the questionnaires at the hospital while the NCCP received 
them in the mail prior to the hospital consultation. Consequently, the cancer patients 
were already in a care situation when completing the questionnaires while the patients 
with NCCP were waiting for help at home. Many patients with NCCP have a history 
of search for medical care without satisfactory effect on their health status. These 
patients presumably look forward to the consultation at the pain clinic and one has to 
take into account that their situation may contribute by creating a bias through 
patients who are especially aroused with regard to pain and even some who may 
instrumentally report worse symptoms in order to get help. One might speculate 
weather this is reflected in the data that actually demonstrated worse pain in the 
patients with NCCP compared to those with advanced cancer. If this difference in 
mode of administration contributes mainly on the absolute scores and less on the 
correlation between pain intensity and pain’s interference, it will be of less 
importance for our main findings. However, we do not know how this has affected the 
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results and it would have been preferable if the patients with NCCP had been re-
assessed when they had settled after the consultation at the pain clinic. A recent study 
by Fredheim et al. (2008) found that the patients with NCCP reported poorer HRQoL 
in 11 of 15 EORTC QLQ-C30 scales (including pain) compared to cancer patients in 
palliative care (Fredheim et al. 2008). This study supports our findings. It is discussed 
whether this gap between HRQoL in patients with NCCP and advanced cancer 
disease may be explained by the Calman gap. Calman explained such differences as a 
consequence of differences between experienced and expected health status (Calman 
1984). While the patients with advanced cancer to a larger degree accept that their 
health status decreases, the patients with NCCP may struggle more with maintaining a 
normal level of functioning. This may lead to frustration and feelings of loss when 
they realise that they do not perform as well as they expect to do. 
The number of patients who completed the questionnaires was different in the groups, 
maybe as a consequence of different data collection procedures. The NCCP patients 
may have perceived the completion of the questionnaires as more relevant and 
important for their own treatment as their completion rate was higher than in the 
cancer group. However, this finding could also reflect worse health status in the 
cancer group leading to more missing items. These data support our hypothesis that 
the BPI is too complicated and burdensome to use in patients with advanced disease. 
Another limitation regards the fact that most cases are concentrated in the central part 
of the pain scales and we have fewer observations in the top and bottom of the score 
distribution. However, the main results are found as group differences within the 
central parts of the scale (e.g. between intensity scores of 3 to 7 in pain interference 
with physical functioning), at those parts with most observations. 
The selection of patients into the study was skewed with regard to pain. All 
participating cancer patients were on opioids and the NCCP patients were recruited 
from a specialized pain clinic at a university hospital, denoting that they had been ill 
for a long time. However, a positive consequence of this selection, for the study, was 
that these patients had pain. 
In conclusion, assessment of pain’s interference with physical functions seems to be 
biased by general level of physical function in cancer patients. A recent study 
supports this conclusion by reporting that the interference scales could be invalid in 
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cancer patients, since they tend to be influenced by their general level of functioning 
while responding to items regarding pain limited functioning (Stenseth et al. 2007). In 
our data, the patients with NCCP report more pain’s interference with psychological 
functions with increasing pain intensity compared with cancer patients. Cleeland 
suggested that assessment of pain intensity is less valuable compared to assessment of 
pain’s interference in patients with NCCP (Cleeland 1989). Our results may indicate 
the opposite for cancer patients in PC. According to the present results the assessment 
of pain’s interference with functions is complicated and the patient’s diagnosis should 
be taken into account for valid interpretation of such scores. 
4.1.3 Summary 
Our two studies on self-report based cancer pain assessment indicate a shortage in the 
existing alternatives; the tools’ content is not optimal, they are burdensome to use and 
parts of the assessments may be invalid (e.g. assessment of pain’s interference with 
functions as done in the BPI). As a response to these challenges we established and 
co-ordinated a panel of PC experts in clinic and research, who gave recommendations 
for the development of new and improved pain assessment tools. 
4.2 Behavioural pain assessment 
Both studies III and IV focus on the psychometric properties and clinical feasibility of 
the Doloplus-2 and are mainly discussed together in the following section. Studies III 
and IV both tested the criterion validity of the Doloplus-2. The further focus in study 
III was on the translation of the Doloplus-2 into Norwegian and on the exploring of 
the feasibility of the tool in Norwegian nursing homes. In study IV the additional foci 
were on the inter-rater reliability of the Doloplus-2 and on the use of a pain expert as 
a criterion for pain. In these two studies the Doloplus-2 demonstrates low criterion 
validity, which may indicate poor content and construct validity. Both our studies 
indicate that the psychosocial domain performed inadequately and this finding was 
recently supported in another study (Zwakhalen et al. 2006a). To study cognitively 
impaired nursing home residents was a greater challenge than we had anticipated. The 
diagnostics of the patients were not as comprehensive as one could have wished for 
and the personnel at the nursing homes are few per resident and there is a general lack 
of educated personnel. A recent study that explored the validity and clinical 
usefulness of the Doloplus-2, the Pain Assessment in Advanced Dementia Scale 
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(PAINAD) (Warden et al. 2003) and the Pain Assessment Checklist for Seniors With 
Limited Ability to Communicate (PACSLAC) (Fuchs-Lacelle and Hadjistavropoulos 
2004) also failed to report a robust conclusion with regard to the validity of the 
Doloplus-2 due to problems with the design (Zwakhalen et al. 2006a). 
4.2.1 Subjects 
Most patients were demented and stable in level of cognitive function while a 
minority of the patients, especially some patients at the Geriatric ward in study IV, 
had acute incidents of delirium and unstable levels of cognitive function. Apart from 
that, all the patients in the studies were judged as too cognitively impaired to make 
valid self reports of pain. They were a heterogeneous group with regard to age, level 
of cognitive function as measured by the MMSE, level of independence in ADL as 
measured by the Barthel Index, and general health status. In study III we approached 
nursing homes where we knew that the patients were diagnosed with cognitive failure. 
At these special shared house wards for demented people we had an appropriate 
population for testing a behavioural assessment tool. However, our results indicate 
that the level of pain was low in this particular group. Consequently, we aimed at 
other nursing home patients in study IV where we included patients from regular 
nursing homes (in opposition to shared housings for demented) as well as patients 
from the geriatric ward at St. Olav’s University Hospital. 
4.2.2 Pain 
It is a limitation in these two studies combined that the patients were clustered at the 
low pain levels, a fact that may have negative effect on both the internal and the 
external validity. In international studies the pain prevalence in nursing home patients 
is generally reported between 45% to 84% (Herr 2002;Manfredi et al. 2003). In 
Norwegian nursing homes, pain has also been regarded as prevalent and described by 
prevalence numbers of 47% to 53% (self-report) and 44% to 67% (nurses’ reports) 
(Jordhoy et al. 2003;Nygaard and Jarland 2005a;Nygaard and Jarland 2005b). 
According to our pain experts, 58% in the first Doloplus-2 study and 64% in the 
second study had a positive pain score (NRS-11 > 0). Consequently, our prevalence 
numbers are in accordance with other studies. However, these prevalence numbers 
regards positive pain scores, and that may not be equivalent to clinically significant 
pain.
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The study by Jordhoy et al. (2003) assessed pain by EORTC QLQ-C30 and reported 
mean values of pain intensities at trial entry 45 (± sd 30), follow-up mean score of 48, 
and one month before death the mean score was 58 (possible range of scores 0-100), 
while the two studies by Nygaard and Jarland only report presence of pain. This may 
be a consequence of the fact that most behavioural tools are concerned with counting 
the presence of pain behaviours, not with ranking pain intensity. It is our experience 
that it is more difficult for patients with cognitive impairment and for proxy raters to 
report intensity than just the presence of pain or no pain. Therefore we do not know 
whether our patients’ low levels of pain are unrepresentative or not, but Jordhøy et 
al’s (2003) data did also report the pain levels to be moderate. It is problematic when 
pain frequencies are presented as pain prevalence. A pain score of one or two on a 
NRS-11 may not constitute a clinically significant level of pain and consequently the 
prevalence may seem higher than it really is. A recent study by Leong et al. (2006) 
summarized that low levels of pain in validation studies of behavioural assessment 
tools in nursing home patients, are a well known “problem” (Leong et al. 2006). We 
anticipated to find higher levels of pain than we did. One may speculate if this mainly 
reflects that the published numbers of pain prevalence in elderly are artificially high. 
Scherder, Sergeant and Swaab (2003) stress the importance of relating 
neuropathology to pain in patients with dementia. Reviews have demonstrated that 
pain is experienced differently in patients with different diagnoses. Patients with 
Alzheimer’s disease (AD) are often said to have decreased pain experiences while 
those with a vascular dementia may have increased pain sensations (Scherder et al. 
2003). As previously stated, many patients who were included in Study III and IV 
have never been properly diagnosed for their dementia and this seems to be a common 
problem in nursing homes. The internal distribution of subjects with AD and with 
vascular dementia in a study sample may contribute on the identified pain prevalence 
in the population. 
As a result of the low levels of pain we cannot present evidence regarding the 
psychometric performance of the Doloplus-2 in patients with high levels of pain. On 
the contrary, our results provide a comprehensive evaluation of the Doloplus-2 in a 
heterogeneous group of patients, from five different nursing homes and one geriatric 
hospital ward, with no to moderate pain. 
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4.2.3 Limitations related to design 
Both studies rely on the assumption that a single expert statement is a valid criterion 
for pain. In study III, the physicians responsible for the patients’ treatment acted as 
the experts, while we used one expert in all patients in study IV. We tested the inter-
rater reliability of this expert’s performance (study IV) in a sub-sample (N=15) and it 
was satisfactory. In the papers (especially in paper IV) we have discussed the pros and 
cons of this design. Our main argument for using pain experts as criterion was that we 
wanted to test the performance of the Doloplus-2 in populations with patients unable 
to self-report. The original French validations were performed in patients who were 
able to self-report pain and in these patients the Doloplus-2 score was compared to a 
VAS score given by the patient and the most recent Doloplus-2 study also adopted 
this design (Wary et al. 2001;Wary et al. 2003;Pautex et al. 2007). Hadjistavropoulos 
and Craig (2002) argued for a different understanding of pain behaviours performed 
by those with higher level of mental functioning to those with cognitive impairments 
(Hadjistavropoulos and Craig 2002). In cognitively intact, pain behaviour will be 
guided by a communicative intent and the pain stimuli will be cognitively evaluated 
in front of the pain expression. In cognitively impaired, pain behaviours will lack 
conscious communicative control. As such, pain behaviours among cognitively 
impaired are more related to pain reducing behaviour while the cognitively intact also 
will use pain behaviour to call for help from others. It is therefore important that the 
testing of behavioural assessment tools are performed in patients who are too 
cognitively impaired to self-report, as done in our two studies. 
The study design could have been strengthened by a Doloplus-2 test-retest with 
administration of analgesics, in the pain patients, in between the assessments. Such a 
design would have provided information on the Doloplus-2’s responsiveness towards 
change and it would have contributed with important information regarding pain or 
not in patients where there was doubt. However, such a design would have demanded 
substantial additional resources and it was not found feasible to perform at this 
moment. 
The combined experience from studies III and IV indicates that the mode of 
administration had an important impact on the criterion validity of the Doloplus-2 as 
concordance between the Doloplus-2 scores and the expert’s scores were higher in 
those cases were the Doloplus-2 was administered by the most experienced and 
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skilled administrators. Study III indicated criterion validity in the Doloplus-2 and here 
the Doloplus-2 administration was a co-operation between a nurse/ nurse assistant and 
a last year medical student with special interest in geriatrics. In study IV we found the 
same pattern of concordance between domains of the Doloplus-2 and the expert’s 
ratings in a subgroup of 16 patients assessed by a geriatric expert nurse who was the 
most experienced Doloplus-2 administrator in study IV. The Doloplus-2 would be a 
more valuable tool if it was valid in the hands of personnel with moderate skills in 
understanding pain behaviour in those with cognitive impairments, but our results 
indicate a need for high competence. New studies on the Doloplus-2 should take these 
considerations into account when recruiting Doloplus-2 administrators. 
The lack of data regarding analgesic use in the Doloplus-2 studies may be a weakness. 
For instance, analgesic efficacy might fluctuate throughout the 24 hour period and 
could lead to different behavioural expressions (i.e., analgesics may change behaviour 
independent of pain). Also, comparing across raters who are assessing patients with 
potentially different levels of analgesia can lead to discordant ratings. Due to 
recommendations from the regional ethical committee (REK) and the Norwegian 
Social Science Data Services regarding the anonymity of the patients, the use of 
analgesics was not recorded. However, the aim of the studies was to assess pain 
behaviour reflecting the experience of pain. We therefore did not find it necessary to 
record pain medication since lack of pain behaviour caused by adequate medication or 
absence of pain would be treated as similar outcomes in the analyses. 
Our Doloplus-2 studies differ from several other validation studies of behavioural 
pain assessment tools in that we found little association between the behavioural 
assessment tool and the criterion. An explanation for this divergence may be that we 
also used less educated and experienced Doloplus-2 administrators compared to other 
similar studies. The intention behind the recruitment of enrolled nurses and assistant 
nurses was that they are the personnel at Norwegian nursing homes in highest number 
and with most patient contact. In the validation of the PAINAD (Warden et al. 2003) 
and the PACSLAC (Fuchs-Lacelle and Hadjistavropoulos 2004), experienced 
registered nurses participated as administrators, often also in teams of two for each 
patient. The validation of Pain Assessment for the Dementing Elderly (PADE) 
(Villanueva et al. 2003) was more similar to our design in that nurse assistants 
performed most of the administration, though under supervision of a registered nurse. 
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The authors hypothesized that the demented patients’ high agitation in the verbal 
domain and low in the physical would be an indicator of pain and used this as a pain 
criterion. Our experience suggests that this is a weak pain criterion as there may be 
many other causes than pain, effecting upon the level of agitation in this group of 
demented patients. Further, the authors report correlation coefficients between 0.396 
and 0.421 comparing the PADE to the Cohen-Mansfield Agitation Inventory (Cohen-
Mansfield 1996;Villanueva et al. 2003). Although significant correlations, these are in 
our opinion too low to be interpreted as signs of good validity in the PADE as done 
by the authors (Villanueva et al. 2003). 
The French constructors of the Doloplus-2 suggest a cut-off score of five points (scale 
runs from 0 - 30) as indicative of pain (Collectif Doloplus 2006). In both our studies 
the Doloplus-2 produced a large number of false positive pain cases (Table 2). 
Table 2: Number of pain-free patients (N=132). 
Pain scores of 0 Study III, N=59 Study IV, N=73 Sum 
Expert score 25 (42%) 26 (36%) 51 (39%) 
Doloplus-2 9 (15%) 5 (7%) 14 (11%) 
Sensitivity of 
the Doloplus-2* 
91% 96%
Specificity of 
the Doloplus-2* 
24% 12%
*Without the cut-off score of five 
If we apply the cut-off score of five, the results change. Then 30 patients are rated as 
pain free by the Doloplus-2 in study III and 27 in study IV (equivalent numbers to the 
experts). In paper III we argued against this cut-off score since it was not evidence-
based. The recommended cut-off would have reduced the seemingly false positive 
pain cases in our two studies by increasing the specificity of the Doloplus-2. In our 
data a Doloplus-2 score below five may still indicate pain, especially if a patient 
displays one of the most valid behaviours. The proportion of false positive and 
negative pain cases may be a consequence of low levels of pain in our study 
population. Combining the results from studies III and IV (N=132), 22 patients (10 in 
study III and 12 in study IV) had a Doloplus-2 score under five and an expert score 
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above zero and one of these patients had a high expert pain score of five. These 
patients would have formed a 17% of false negative pain cases if the cut-off score was 
applied. Our data indicates that some sensitivity in the tool should be sacrificed for 
higher specificity. 
4.2.4 Summary 
The assumption behind behavioural pain assessment tools like the Doloplus-2 is that 
health care personnel can provide valid observations of pain behaviour and express 
these in a standardized form. Our studies question this assumption. 
Taken all discussed limitations with the study designs into account, one should be 
cautious when interpreting the internal and especially the external validity of our two 
studies on the Doloplus-2. Issues with the selection of a proper pain criterion are 
related to the internal validity of the studies and as described the use of a single pain 
expert is debatable. The external validity is weakened by the fact that we had a 
homogenous group with regard to pain. However, it is our opinion that our two 
studies have disclosed some serious problems both with the administration of the 
Doloplus-2 and with false positive or false negative pain cases as assessed by 
Doloplus-2. Both issues are closely related to the psychosocial domain and suggest 
that major revisions should be made to the tool. It is also important to note that some 
patients with severe levels of pain may have low presence of pain typical behaviours 
and therefore receive low Doloplus-2 scores (American Geriatrics Society 2002). This 
may constitute a general challenge against the concept of behavioural pain 
assessment. Consequently, it will also be of importance to search for other clues of 
pain in these patients and incorporate this knowledge into future tools. 
4.3 Suggestions for future research 
Our studies have indicated that both the BPI and the Doloplus-2 are insufficient in 
their psychometric performance and coverage of the pain problem. Consequently, 
better assessment tools are needed. For self-reported pain assessment we have, in 
collaboration with the EAPC research network and with an EU grant, started the 
development of a new and improved computer based assessment tool. This tool 
includes pain among other symptoms and it is based upon the recommendations given 
by the expert panel in study I. 
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The future of Doloplus-2 is uncertain. From the beginning of this study in late 2003 
the Doloplus group has announced that a Dololus-3 is under development. To our 
knowledge, this work is still in progress and the results from our studies will 
constitute important input. Meanwhile the Checklist of Nonverbal Pain Indicators 
(CNPI) (Feldt 2000) offers an interesting alternative that should be thoroughly 
evaluated in more patients (Zwakhalen et al. 2006b). The CNPI is brief, with only six 
items scored for the presence, in rest and in movement, of vocal complaints, facial 
expressions, bracing, restlessness, rubbing affected areas, and verbal complaints 
(Feldt 2000). These items cover the same domains that those in the Dololus-2 which 
had best psychometrical functioning in our studies. 
One may also speculate whether the pain indicators repetitively used in all behavioral 
pain assessment tools are really valid. If not, the whole approach to behavioral pain 
assessment needs to be re-evaluated before the construction of new and improved 
assessment tools. Further development of validation methodology is important and it 
is our opinion that such validation should take place in patients unable to self-report 
pain. In our two studies on the Doloplus-2 we have suggested a design with expert 
raters, which should be elaborated on and improved in order to achieve a solid 
criterion for future testing of behavioural pain assessment tools. The use of a single 
expert is a criterion with obvious limitations and future research should use at least a 
combination of two pain experts. Other behavioural pain assessment tools can be used 
as sub-criterions and a verbal rating scale may be used for self-report in some patients 
that are communicative. Test-treatment with analgesics may also constitute a valid 
criterion and could be used in addition to the experts. 
An effort should also be made to produce guidelines for when to use self-report based 
questionnaires and when to use observational tools. Perhaps a short mental screening 
tool in front of the pain assessment could assign patients to self-report if such is 
applicable. By now there are no guidelines to advise healthcare personnel as to when 
self-report is invalid and behaviour observational tools should be used. EAPC and 
AGS are both in a position to contribute with a much needed guidance on this issue. 
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5. Conclusions 
In response to our three study objectives we have reached the following conclusions: 
1. The most relevant pain dimensions for assessment in PC are pain intensity, 
temporal pattern, treatment and exacerbating / relieving factors, pain location, 
and pain interference. Intensity is most important while the subsequent four 
dimensions are recommended for comprehensive assessment. 
a. The 80 reviewed assessment tools contained 11 different pain dimensions 
(in alphabetic order): Benefits from treatment, Pain affect, Pain beliefs, Pain 
duration, Pain history, Pain intensity, Pain interference, Pain location, Pain 
quality, Pain relief (exacerbating/relieving factors), Temporal patterns, 
Treatment and exacerbating / relieving factors. 
b. The content validity of the existing tools is questionable for assessment in 
PC as none of the tools meet the experts’ recommendations for such 
assessments. 
2. Patients with cancer pain report higher levels of pain’s interference with 
physical functions while patients with NCCP report more interference with 
psychological functions. 
a. Patients with advanced cancer seem unable to distinguish between pain’s 
interference with functions and impaired functions caused by the disease. 
On this background one might question the recommendation by the expert 
panel in Study I on the relevance of assessing pain’s interference with 
functions.
3. The Norwegian Doloplus-2 demonstrated satisfactory criterion validity in the 
pilot study, but these results were weakened by a more thorough study. Valid 
Doloplus-2 assessment seems to depend on high administration skills. 
a. The Doloplus-2 item for facial expressions explained most of the total 
variability in the expert score followed by the items for protective body 
postures adopted at rest, communication, and somatic complaints. 
b. The feasibility of the Doloplus-2 is limited by the need for specific 
administration and interpretation skills. 
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c. The inter-rater reliability of the Doloplus-2 seems to be satisfactory, but is 
of limited value since the tool does not demonstrate satisfactory criterion 
validity. 
d. A comprehensive and promising pain criterion in future studies may consist 
of a combination of pain ratings from at least two pain experts who have 
access to relevant information about the patient, pain ratings from other 
behavioural pain assessment tools, a verbal rating scale for self-report of 
present pain intensity when applicable, and test-treatment with analgesics. 
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Errata
In paper II the published paper had been revised by the editorial office after the first 
author had approved the proofs. This resulted in a new title and the authors’ concept 
of non-malignant chronic pain was changed into noncancer chronic pain. 
In the last paragraph at page 220 before the new chapter Measures, the sentence 
should read: Patients in both groups were 18 years or above and the cancer patients
were evaluated and found to be cognitively competent to complete… 
The patients with NCCP were not screened with regard to cognitive functioning. 
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Abstract
Inadequate pain assessment prevents optimal treatment in palliative care. The content of
pain assessment tools might limit their usefulness for proper pain assessment, but data on the
content validity of the tools are scarce. The objective of this study was to examine the content
of the existing pain assessment tools, and to evaluate the appropriateness of different
dimensions and items for pain assessment in palliative care. A systematic search was
performed to ﬁnd pain assessment tools for patients with advanced cancer who were receiving
palliative care. An ad hoc search with broader search criteria supplemented the systematic
search. The items of the identiﬁed tools were allocated to appropriate dimensions. This was
reviewed by an international panel of experts, who also evaluated the relevance of the
different dimensions for pain assessment in palliative care. The systematic literature search
generated 16 assessment tools while the ad hoc search generated 64. Ten pain dimensions
containing 1,011 pain items were identiﬁed by the experts. The experts ranked intensity,
temporal pattern, treatment and exacerbating/relieving factors, location, and interference
with health-related quality of life as the most important dimensions. None of the assessment
tools covered these dimensions satisfactorily. Most items were related to interference (231) and
intensity (138). Temporal pattern (which includes breakthrough pain), ranked as the second
most important dimension, was covered by 29 items only. Many tools include dimensions
and items of limited relevance for patients with advanced cancer. This might reduce
compliance and threaten the validity of the assessment. New tools should reﬂect the clinical
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Introduction
Pain is among the commonest symptoms in
cancer patients receiving palliative care.1,2
Proper pain assessment is generally considered
a prerequisite for proper pain treatment, but
despite dedicated efforts, studies demonstrate
that pain still is not adequately assessed, and
as such, not satisfactorily managed.3e6 In a sur-
vey among 897 physicians in the Eastern Coop-
erative Oncology Group, 76% reported poor
pain assessment as the single most important
barrier to adequate pain management.7
An Expert Working Group of the European
Association for Palliative Care (EAPC) re-
viewed the status of the use of pain measure-
ment tools in palliative care research.8 Based
on the literature and the experts’ opinions,
the group gave recommendations on pain as-
sessment in palliative care research. The selec-
tion of tools should be based on the study
population and the speciﬁc study design. For
adult patients without cognitive impairment,
multidimensional pain assessment with the
Brief Pain Inventory short form (BPI-sf)9,10
was recommended.8 The Short Form McGill
Pain Questionnaire (SF-MPQ)11 was recom-
mended for studies that speciﬁcally assess
pain quality, such as studies focusing on diag-
noses and characterization of various pain syn-
dromes.8 For simple assessment of changes in
pain intensity, Numerical Rating Scales
(NRS) were recommended.8
Another recent review evaluated the psycho-
metric performance of pain assessment tools
in cancer patients in general, both in the clinic
and in research.12 This review demonstrated
that single-item unidimensional tools, such as
Visual Analogue Scales (VAS) and NRS, were
psychometrically satisfactory for assessment of
pain intensity in clinical settings. However,
these should be used with caution in palliative
care patients, particularly because the ability to
complete the VAS scales declines with disease
progression.12 In line with the advice of the
EAPC Expert Working Group and as empha-
sized in other studies,8,12e16 it was recommen-
ded that pain assessment in cancer clinical
care and research should include dimensions
additional to intensity. Fewer than 3% of the
studies in the review addressed issues of con-
tent validity in pain assessment tools, leading
to a recommendation that examination and
evaluation of the content should be the focus
of future studies.12
Both reviews recommended selection of
a pain assessment tool on the basis of its psy-
chometric performance. No direct recommen-
dations were given on the basis of the tools’
contents, even though both reviews recom-
mended tools for multidimensional pain as-
sessment. However, the literature has shown
that many of the present multidimensional
tools are burdensome to use for both clinicians
and patients, especially in populations with ad-
vanced disease.8,15,17e20 The SF-MPQ was re-
garded as too demanding to use by the EAPC
Expert Working Group and others.8,17 A study
using both the full version of the BPI and the
BPI-sf showed that fewer than 58% of the
patients completed all questions in the full
version, returning partially completed ques-
tionnaires.18 The study concluded that the
BPI was too burdensome for both patients
and administrators.18 The BPI-sf, on the other
hand, was regarded as not sufﬁciently compre-
hensive.18 Despite the shorter format, two
European studies, includingmore than 400 pal-
liative care cancer patients, demonstrated that
35% and 40% in the two samples, respectively,
returned incomplete BPI-sf questionnaires.19,20
To our knowledge, evidence-based informa-
tion regarding the content of pain assessment
tools is scarce. At present, we are not aware of
any studies that have speciﬁcally addressed the
content of pain assessment tools with speciﬁc
relevance for cancer pain assessment in
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palliative care. The lack of knowledge on what
to assess combined with insufﬁcient perfor-
mance of the recommended tools made us
launch the present study, with the following
aims: 1) to examine the content of the existing
pain assessment tools for cancer pain in pallia-
tive care practice and research, 2) to evaluate
the relevance of different dimensions and
items for cancer-pain assessment in palliative
care practice and research by consulting
a panel of international experts, and 3) to ex-
plore the need for additional items, dimen-
sions, or assessment tools speciﬁc to palliative
care.
Methods and Materials
The methodology consisted of two ap-
proaches. First, two literature searches were
conducted in order to identify the content of
existing pain assessment tools. Second, an ex-
pert panel was consulted to evaluate and clas-
sify the content of the tools identiﬁed by the
literature searches.
Literature Searches
Two literatures searches were conducted.
First, a systematic search on pain assessment
tools used in palliative care was performed.
This was supplemented by a broader search
for pain assessment tools used in other popula-
tions. To be included in the systematic search,
the title or abstract should describe the follow-
ing: 1) a self-report method used for pain as-
sessment or the name of an assessment tool
explicitly used for self-report of pain, and 2)
a sample with adult advanced cancer patients
receiving palliative care. The search was fur-
ther restricted to publications in English.
Case reports, editorials, letters, and commen-
taries were excluded.
A systematic, computerized literature search
in PubMed (MEDLINE) and Cancerlit (1966
to February 2003), PsychInfo (1972 to Febru-
ary 2003), and Cinahl (1970 to February
2003) was done. The Cochrane Library review
group for Pain, Palliative and Supportive Care
was also consulted. The following key words
and medical subject headings were used: Pain
assessment or Pain measurement combined with
Palliative care or Palliative medicine. All titles
and abstracts were examined in relation to
the inclusion criteria. When a tool was named
and/or described as a measure for pain, the
full paper was examined for further informa-
tion. If applicable, the original paper describ-
ing the construction of the identiﬁed tool
was examined for further information.
To ensure a more complete coverage of pain
assessment tools, we decided to broaden the
study with an ad hoc search applying wider
search areas in the Ovid-MEDLINE journal ar-
chive and the BIBSYS book archive. The aim
was to identify self-report-based assessment
tools for adults including at least one item
for pain assessment. This included assessment
tools developed for, and used, in patient popu-
lations other than palliative care. The aim was
to identify supplementary information regard-
ing the pain dimensions being covered by tools
developed for other patient populations. The
terms in the searches were Pain assessment or
Pain measurement. The Ovid-MEDLINE-bases
from 1989 through February 2003 were
searched. Because this was a supplementary
ad hoc search and because of the vast number
of publications on pain assessment in general,
the following MEDLINE limitation options
were deployed: English language, abstracts
available, humans, all adult (19 years or
above), and full text. The Norwegian Search
Library database BIBSYS (international) was
searched for books. The results from the two
searches were combined and duplicates were
deleted.
The titles and abstracts of the papers were
browsed in order to identify those including
information about assessment tools. When
a tool was named and described as a measure
for pain, the full text paper was consulted.
Tools especially designed for measurement of
back and neck pain and headache/migraine
were included, as they are numerous and had
the potential to present pain assessment in-
formation of general value. We decided not to
include ad hoc questionnaires or tailor-made
tools for the following specialized areas of in-
terest: ocular pain, ankle and Achilles pain,
myofascial pain, mucositis, dental pain, wheel-
chair user’s shoulder pain, and jaw pain, as
their potential for adding general cancer
pain information for palliative care was evalu-
ated as small. The original papers describing
the construction of the identiﬁed tools were
examined for further information about the
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tool. The books were evaluated by the back-
ground information provided by the BIBSYS
site and by browsing the titles. Only books
that seemed to be devoted to pain assessment
as the main topic were included. The Oxford
Textbook of Palliative Medicine,21 Quality of Life:
Assessment, Analysis and Interpretation,22 and
Quality of Life and Pharmacoeconomics in Clinical
Trials23 were also included because they pres-
ent relevant assessment tools and were in the
ﬁrst author’s possession.
Pain Dimensions and Items
The terms pain dimensions and pain domains
are used interchangeably in the literature on
pain. Intensity is typically referred to as a dimen-
sion, while location is commonly described as
a domain. However, as both concepts refer to
aspects of the pain experience, the term dimen-
sion is used throughout the present work.
An item is operationalized in the form of
a question or a statement.22 For example, an
item conceptualized as ‘‘pain intensity’’ might
be operationalized like ‘‘How bad is your
pain?’’ or ‘‘My pain is as severe as:.’’. To sum-
marize the numerous items across tools, we de-
ﬁned an item as a question or a statement that
requires an answer. A question such as no. 21
from the BPI,24 ‘‘I believe my pain is due to:’’,
where the respondent is provided with three
choices, was conceptualized, therefore, as
three separate items. Body maps for pain
were counted as one item (BPI), or one item
per question asked in tools that ask about
pain in different body parts (Regional Pain
Scale25). We deﬁned a pain item as a ques-
tion/statement that explicitly refers to pain,
is related to pain (headache), or at least in-
cludes pain (among other symptoms) in the
wording or in the questionnaires’ guidelines.
Thus, items about psychological distress in
a pain assessment tool were not counted unless
directly phrased as pain-related distress. Global
items about how the present health situation
interferes with health-related quality of life
(HRQOL) were not deﬁned as pain items, in
contrast to items speciﬁcally asking about
how pain, alone or in combination with other
symptoms, interferes with a speciﬁc function.
Content Categorization
All the included assessment tools and the pa-
pers describing the construction of the tools
were examined for information about the con-
tent expressed by their pain dimensions and
the items covering them. All dimensions that
were either described as assessed by the tool
developers or that were named in the tool
were included in a list of assessed pain dimen-
sions. The tools are presented in Table 1, with
their pain dimensions and number of items
within each dimension. In some tools, all di-
mensions were not speciﬁed by the construc-
tors, and had to be conceptualized on the
basis of the items’ content. The items covering
the dimensions that were not deﬁned were
compared to items from other tools with
known dimensionality in order to examine
the similarity. Items asking about severity, in-
tensity, and amount of pain were consequently
named intensity items, while items asking
about where it hurts were classiﬁed as location
items. This was performed by the ﬁrst author
and later an international expert panel was
asked to delete or add other dimensions in or-
der to achieve coverage of all necessary dimen-
sions for palliative care (to be described later).
In cases of uncertainty about the actual dimen-
sions within a tool, the dimensions were placed
in brackets (Table 1). If only one of the dimen-
sions was obvious, it was decided to label the
tool as unidimensional, with the other poten-
tial dimensions listed in brackets. In approxi-
mately 30% of the tools, we assigned items to
dimensions other than those originally sug-
gested by the constructors. This is exempliﬁed
by the Oswestry Disability Index,54 item no. 1:
‘‘Pain killers give complete relief from pain.’’ This
item was named pain intensity by the devel-
opers, but when comparing this wording
against similar items in other tools, we classi-
ﬁed it as also assessing effects of treatment.
In cases with disagreement between tool devel-
opers’ characterization of included dimen-
sions and our comparisons between tools,
dimensions were included in addition to the
developers’ dimensions (that always were
taken into account). The categorization of
the dimensions and items was later reviewed
by the expert panel.
Expert Panel
In line with the study objectives, an interna-
tional expert panel was established for the
identiﬁcation and the evaluation of the impor-
tance of the different pain dimensions for
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palliative care pain assessment. This panel con-
sisted of six physicians who are experienced
pain and palliative care specialists in both clin-
ical practice and research from ﬁve European
countries and members of the EAPC Research
Network. The expert panel was involved in two
steps.
First, the identiﬁed pain dimensions were al-
phabetically listed and mailed to the experts
together with an instruction sheet. They were
asked to consider both clinical and research
objectives combined, and to provide one
rank of the dimensions for relevance and
importance for pain assessment (clinicalþ
research) in palliative care. The experts were
instructed to add new dimensions if they con-
sidered any to be missing, and to delete those
that they found inappropriate or unnecessary
to assess in palliative care. Thus, the most im-
portant dimension was to be ranked as num-
ber one, the second most important as two,
and so on. The overall importance of each di-
mension was calculated as the average of the
expert rankings. Thus, the lowest total score
signiﬁed the most important dimension. Di-
mensions that were deleted were all given the
highest score for the purpose of analyses.
The ﬁve top-ranked dimensions were retained
for the next phase of this study.
Based on the experts’ deﬁnitions and selec-
tion of pain dimensions, the ﬁrst author as-
signed items to the appropriate dimensions.
As the second expert task, the list with all the
appropriate items assigned to the ﬁve high-
est-ranked dimensions was mailed to the ex-
perts. This time they were asked to evaluate
the assignments, to move items to the appro-
priate dimension if they disagreed with our
suggestions, and to delete items that they
deemed inappropriate for palliative care.
Results
Literature Search
A total of 412 citations were retrieved from
the systematic search, with 10 being duplicates.
Examination of the titles and the abstracts iden-
tiﬁed 48 papers that met our inclusion criteria.
The majority of the excluded studies failed to
meet the criterion regarding advanced cancer
patients receivingpalliative care. The searchdis-
closed 16 different tools for pain assessmentIl
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used inpalliative care studies. Themost popular
pain assessment tool was the VAS, used in 21
(44%) of the included studies, followed by
NRS with 8 (17%), and the MPQ and the BPI
with 6 (13%) each (the tools that were found
in the systematic literature search are marked
with an * in Table 1).
The ad hoc search in the Ovid-MEDLINE
databases resulted in a total of 18,021 hits as
follows: pain assessment produced 919 hits, while
pain measurement identiﬁed 17,102 papers.
When the searches were limited according to
our criteria, the numbers were reduced to 48
and 1,343, respectively. The full text limitation
that was applied to this search only, reduced
the number of hits in the ad hoc search by
85%. After duplicates were deleted, 1,359 pa-
pers were eligible for this report. The BIBSYS
search identiﬁed 100 books.
The entire literature search generated 80
different assessment tools containing at least
one pain item. The tools were categorized
into Pain Tools (n¼ 48) and General Symp-
tom/HRQOL Tools (n¼ 32). The tools can
be separated into those that assess pain with
a unidimensional approach usually measuring
pain intensity, and the multidimensional tools
that include more than one pain dimension.
Among the 48 Pain Tools, 16 (33%) tools
were unidimensional, and of 32 General Symp-
tom/HRQOLTools, 16 (50%) were unidimen-
sional with regard to pain. The majority of the
unidimensional tools (58%) were single-item
scales such as VAS, Verbal Rating Scales
(VRS), and NRS. Pain intensity was the most
common dimension, targeted in 60% of the
tools.
Forty-eight (60%) of the tools assessed pain
multidimensionally. Sixty-seven percent of the
Pain Tools were multidimensional, compared
with 50% of the General Symptom/HRQOL
tools. Of the multidimensional tools, 38%
were two-dimensional. The most frequently ap-
pearing dimension was intensity, included in
75% of the multidimensional tools. Other fre-
quently occurring dimensions were interfer-
ence, location, and beliefs. These dimensions
were particularly targeted by two kinds of spe-
cialized tools: disease-speciﬁc tools (with a ma-
jority of low back Pain Tools), and tools that
measure pain affect, beliefs, and coping-
related issues in nonmalignant chronic pain
patients.
Pain Dimensions and Items
The search identiﬁed 11 different pain di-
mensions (Table 1). These were, in alphabeti-
cal order: Effects of treatment, Pain affect,
Pain beliefs, Pain duration, Pain history, Pain
intensity, Pain interference with HRQOL,
Pain location, Pain quality, Pain relief (exacer-
bating/relieving factors), and Temporal pat-
tern (dimension descriptions are offered in
Table 2). The three most frequently assessed di-
mensions were: intensity in 55 tools, interfer-
ence in 37, and beliefs in 22, while duration
and history were assessed in six and four tools,
respectively.
The tools contained 1,011 pain items. There
were 893 items in the Pain Tools (88%) and
118 items in the General Symptom/HRQOL
Tools. Most items were formulated as state-
ments or as questions followed by an NRS,
VAS, or VRS.
Expert Panel Evaluation
The expert panel suggested that the dimen-
sions for ‘‘pain relief (exacerbating/relieving
factors)’’ and ‘‘effects of treatment’’ be col-
lapsed into one dimension named treatment
and exacerbating/relieving factors, after the initial
suggestion of one expert and the approval by
the others. The rationale was to make one di-
mension that includes all nontreatment and
Table 2
Pain Dimensions Ranked by Experts According
to Importance for Pain Assessment
in Palliative Care
Pain Dimensions Descriptions
1 Pain intensity How much it hurts, sensory
component
2 Temporal pattern Pain ﬂuctuations, variations in
intensity and occurrence
3 Treatment and
exacerbating/
relieving
factors
Medical and nonmedical
4 Pain location Where it hurts
5 Pain interference How much components of
HRQOL are reduced by pain
6 Pain quality The speciﬁc physical sensation
associated with the pain
7 Pain affect Emotional component of pain,
the unpleasantness and
signiﬁcance of pain
8 Pain duration How long pain has lasted
9 Pain beliefs Attitudes, coping strategies
and beliefs about causes and
consequences
10 Pain history Previous pain experiences
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treatment factors (medical and nonmedical)
that inﬂuence pain. The experts thereby re-
duced the number of pain dimensions from
11 to 10 and ranked them, according to the
perceived importance for pain assessment in
palliative care (Table 2).
Pain intensity was rated as the most impor-
tant dimension by four of the experts and as
the second most important by the two others.
All experts agreed that the ﬁrst ﬁve dimen-
sions were important for pain assessment in
palliative care. The other ﬁve were ranked as
less important. Furthermore, by at least one
expert, each of the last ﬁve dimensions was re-
garded as not important enough to be assessed
in palliative care patients, weighed against the
assessment burden. No additional dimensions
were suggested.
The item distribution for the ﬁve highest-
ranked dimensions, according to the expert
evaluation, is presented in Table 3. The ex-
perts rearranged three items from our original
dimension assignment. All of these were
moved from the intensity dimension to the
treatment and exacerbating/relieving factors
dimension, due to the focus on pain intensity
after medication with painkillers. Four items,
among them the item, ‘‘My life is hardly worth
living with all of this pain,’’32 were deleted be-
cause they were regarded by at least one expert
as inappropriate (unnecessarily offensive) for
use in palliative care.
Pain intensity items could be categorized
into two groups: statements about pain and
questions about pain. The statements include
descriptions of pain sensations, experiences
of intensity level, and items relating intensity
to the need for analgesics. The intensity ques-
tions approached pain intensity in four ways
(according to the tool constructors dimension
deﬁnitions): suffering caused by pain, intensity
of the pain, dependency on analgesics, and
how bad pain has been. Most tools did not in-
clude ‘‘intensity’’ in the wording of the item.
The majority asked about pain, when address-
ing pain intensity.
Tool Content Compared to Expert
Recommendations
Three of the reviewed tools covered all of
the ﬁve highest-ranked dimensions: the Aber-
deen Low Back Pain Scale (AB),27 the World
Health Organization Quality of Life Assess-
ment Tool-Pain Module (WHQOL-Pain),68
and the Pain Assessment Questionnaire for
a patient with advanced disease (PAQ).2 The
latter is not an ordinary questionnaire, but
a pain assessment protocol based on the guide-
lines presented in Management of Cancer Pain:
Clinical Practice Guidelines. The dimensions for
pain quality, beliefs, and pain history (ranked
6, 9, and 10, Table 2) were also covered by
the PAQ guidelines. The WHQOL-Pain tool in-
cluded pain affect, duration, and beliefs (re-
spectively ranked 7, 8, and 9), in addition to
the ﬁve that were recommended.
Discussion
A number of different tools for pain assess-
ment is available. Pain is a complex phenome-
non, however, and evaluation of the content of
the existing tools revealed great diversity of di-
mensions and items. This variety might affect
the validity of pain assessment in general. It
also makes comparisons between studies difﬁ-
cult,3,12 as recently noted in two Cochrane re-
views that concluded that meta-analyses were
impossible to perform due to the use of differ-
ent pain assessment tools.101,102 Among the
studies that were included in the systematic re-
view, the VAS was the most frequently used
Table 3
Number of Items per Dimension
Intensity Temporal pattern Treatment Location Interference
Pain tools 103 18 67 76 206
General symptom/HRQOL tools 35 11 18 17 25
Total 138 29 85 93 231
Items that measure several dimensions are counted once for each dimension. Example: the RPS instructs the patients to rate intensity for a list of
joints and body parts. All 38 items are counted as one item on intensity and one on location. Items in dimensions in brackets (Table 1) were
counted when summarizing the total item number.
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(44%). According to two recent reviews on
pain assessment,8,12 this is suboptimal.
Ten pain dimensions were identiﬁed and
conﬁrmed by the expert panel. The expert
panel regarded ﬁve dimensions as appropriate
for comprehensive pain assessment in both
palliative care practice and research. Although
these ﬁve were considered optimal, the pres-
ent results do not state that all ﬁve dimensions
should be included in all situations. The re-
sponse burden must be weighed against the
need for information, as emphasized in the
EAPC review.8 Intensity was ranked as the most
important dimension, in line with results from
the literature. Thus, it should be included in
most assessments. The subsequent four dimen-
sions are recommended for comprehensive as-
sessment, but optional. Temporal pattern was
regarded as the second most important dimen-
sion. However, only 16% of the tools assessed
this dimension, providing the lowest number
of items (29 items, Table 3). A recent review sup-
ports this lack of focus by demonstrating that
fewer than 2% of the cancer pain tools mea-
sured temporal aspects of pain.12 Temporal pat-
terns are of special interest for palliative care,
because of high prevalence of breakthrough
pain.103 As most tools were developed for other
patient populations, this may explain why tem-
poral aspects were omitted. Theﬁve dimensions
that were recommendedby the expert panel are
covered by three tools only. TheAB includes the
suggested dimensions, and contains items that
may be suitable if the word ‘‘back’’ is removed.
The WHQOL-Pain includes the essential di-
mensions with 149 items covering both pain
and other issues of HRQOL (þ items about
background information), but is too lengthy
for use in palliative care. The PAQ covers the
recommended content, as well as additional di-
mensions, but in its present form it is just an as-
sessment guide and not a tool.2 Assessment in
palliative care should be guided by a ﬁne line
between the need for full information and the
patients’ limited capacity for providing it. Tool
brevity is of great importance for valid and us-
able assessment.Many tools includedimensions
of limited relevance to patients with advanced
disease. Patients with advanced cancer are the
target group for only a few of the multidimen-
sional Pain Tools, such as the Brief Pain Diary
(BPD),30 the BPI-sf, and the PAQ. The BPD
and the BPI-sf are not as comprehensive as
recommended by the experts and the PAQ
needs further development. Many General
Symptom/HRQOL tools contain only one or
two pain dimensions and the number of items
is too few to provide comprehensive pain infor-
mation (Table 1). Consequently, they are inade-
quate as stand-alone pain tools. In addition, as
many as 38% of the multidimensional tools
are only two-dimensional, and do not allow for
comprehensive pain assessment. At the mo-
ment there is no suitable pain assessment tool
that covers the most important dimensions for
pain assessment in palliative care patients ac-
cording to the experts’ recommendations.
Among the 1,011 items, there is great over-
lap, often with minor wording differences
across tools. One example is that most dis-
ease-speciﬁc tools ask about pain intensity in
all the areas of interest, leading to a large num-
ber of items relating to intensity in different
body parts (Table 3). The ﬁnding that most
tools only ask about pain when assessing inten-
sity might highlight a problem. Multidimen-
sional tools, asking about pain interference
with functions, pain quality, and temporal pat-
tern, suddenly shift to a plain ‘‘how bad is your
pain’’ item. Such wording might confuse the
patients to summarize the total pain or to
give pain affect information instead of rating
intensity.
We recognize some limitations in this study.
Due to the vast number of publications in the
ﬁeld, certain limitations were applied to the lit-
erature searches. Consequently, some assess-
ment tools have been missed. The literature
search aimed at covering the range of different
pain dimensions and items with speciﬁc focus
on their content rather than identifying all ex-
isting pain tools. We believe this strategy iden-
tiﬁed a sufﬁcient number of relevant tools for
the purpose of content evaluation. It was chal-
lenging to distinguish the different dimen-
sions, as some were overlapping and strongly
associated with each other. However, the inten-
tion of this study was to give an overview of the
content of pain tools, not to provide an exam-
ination of their psychometric properties. Some
dimension assignments might, therefore, be
debatable. Only physicians participated in the
expert panel and this may limit the generaliz-
ability of the results. However, nurses, psychol-
ogists, and physiotherapists evaluated the
process and they reviewed and approved the
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results from the expert panel. The rationale
behind this choice of experts was that we
wanted an evaluation of the content that was
directly based on experience from palliative
care clinical work and palliative care research.
Thus, within the EAPC research network, phy-
sicians experienced in both the clinic and re-
search were asked to participate.
In conclusion, a large number of pain assess-
ment tools exist, but there is no agreement on
what they should assess. This study offers an
original recommendation on the appropriate-
ness of the content for pain assessment in pal-
liative care. It is our opinion that there is
a need to improve and/or develop an interna-
tional standard for pain assessment in pallia-
tive care in the clinic and in research. A
consensus on these matters might make future
meta-analyses possible. The ideal assessment
tool for patients in palliative care should be
precise (high validity and reliability) and short.
It should be ﬂexible in such a way that it could
be used in different patient populations and
various situations, for example, by assessing
different combinations of dimensions. These
aims can probably be achieved most efﬁciently
by using dynamic computerized tools104,105
rather than paper-based questionnaires. Such
tools can also be integrated with other elec-
tronic data from the hospital’s database and
thereby be suitable for use both in the clinic
and in research.
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Abstract
Background: The Doloplus-2 is used for behavioural pain assessment in cognitively impaired
patients. Little data exists on the psychometric properties of the Doloplus-2. Our objectives were
to test the criterion validity and inter-rater reliability of the Doloplus-2, and to explore a design for
validations of behavioural pain assessment tools.
Methods: Fifty-one nursing home patients and 22 patients admitted to a geriatric hospital ward
were included. All were cognitively impaired and unable to self-report pain. Each patient was
examined by an expert in pain evaluation and treatment, who rated the pain on a numerical rating
scale. The ratings were based on information from the medical record, reports from nurses and
patients (if possible) about pain during the past 24 hours, and a clinical examination. These ratings
were used as pain criterion. The Doloplus-2 was administered by the attending nurse. Regression
analyses were used to estimate the ability of the Doloplus-2 to explain the expert's ratings. The
inter-rater reliability of the Doloplus-2 was evaluated in 16 patients by comparing the ratings of
two nurses administrating the Doloplus-2.
Results: There was no association between the Doloplus-2 and the expert's pain ratings (R2 =
0.02). There was an association (R2 = 0.54) between the expert's ratings and the Doloplus-2 scores
in a subgroup of 16 patients assessed by a geriatric expert nurse (the most experienced Doloplus-
2 administrator). The inter-rater reliability between the Doloplus-2 administrators assessed by the
intra-class coefficient was 0.77. The pain expert's ratings were compared with ratings of two
independent geriatricians in a sub sample of 15, and were found satisfactory (intra-class correlation
0.74).
Conclusion: It was challenging to conduct such a study in patients with cognitive impairment and
the study has several limitations. The results do not support the validity of the Doloplus-2 in its
present version and they indicate that it demands specific administration skills.
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Background
Pain is common in elderly institutionalized patients, and
prevalence rates ranging from 45% to 84% have been
reported [1,2]. Cognitive impairment is also common in
the same group, and more than 50% of nursing home res-
idents have been found to be cognitively impaired [3,4].
A recent review reported prevalence rates in palliative care
patients ranging from 14% to 44%, rising to 90% prior to
death [5].
Proper pain assessment is a prerequisite for optimal pain
treatment [6], but pain assessment is challenging in cog-
nitively impaired patients. Pain is therefore often over-
looked in these patients [3,7-10], leaving them at risk for
sub-optimal pain treatment [7,11,12]. When feasible, self-
report assessment of pain is regarded as the standard
method [9,13]. In patients with mild to moderate cogni-
tive impairment, studies have reported completion rates
ranging from 47% to 100% for simple self-report tools
such as numerical rating scales and verbal rating scales
[3,10]. Ratings of present pain intensity have the highest
completion rates, while self-report of other pain dimen-
sions, like location, interference and temporal patterns, is
more challenging [10].
Cognitive impairment can make self-report tools for pain
assessment invalid and consequently limits their useful-
ness. Observational assessment of behaviour is an alterna-
tive. While self-report tools primarily assess
communicative pain behaviours that are under the sub-
ject's control, observational tools assess behaviours that
are more unconscious or automatic [14]. Behavioural
assessment tools are therefore appropriate in subjects with
impaired higher mental processes. However, thoroughly
validated tools for behavioural assessment are scarce
[10,15], and several reviewers have noted the lack of vali-
dation of the tools for behavioural pain ratings in the cog-
nitively impaired [2,7,10,15-17]. Although data are
limited, a recent review rated the psychometric aspects of
12 behavioural assessment tools according to several
quality judgement criteria. Five tools (in English versions)
received a satisfactory evaluation of validity and reliability
[17]: the Abbey Scale [18], the Pain Assessment for the
Dementing Elderly (PADE) [19], the Pain Assessment in
Advanced Dementia Scale (PAINAD) [20], the Pain
Assessment Checklist for Seniors With Limited Ability to
Communicate (PACSLAC) [21], and the Doloplus-2 [22].
The review concluded by recommending the PACSLAC
and the Doloplus-2, stating that they seem promising but
required further testing [17].
The Doloplus, launched by Bernard Wary in 1992/93, was
originally a 15-item clinical tool for proxy rating of pain
in elderly patients with cognitive failure [22,23]. It was
based on a tool for behavioural assessment of pain in chil-
dren with neoplastic disease (Douleur Enfant Gustave
Roussy scale) [22,23]. In 1995, the Doloplus was refined
by a French/Swiss network of geriatricians, resulting in the
present ten-item version (Doloplus-2 [22]). A Doloplus-2
assessment is performed by a proxy-rater who observes
the subject and evaluates the presence of ten pain-related
behaviours from 0 to 3 – representing increasing presence
of the behaviour [22,24]. These include: verbal com-
plaints, facial expressions, protective body postures, pro-
tection of sore areas, disturbed sleep, functional
impairment in activities of daily living (washing and
dressing, and general mobility), psychosocial reactions
such as behavioural problems, and changes in communi-
cation or social life. Authors of the Doloplus-2 suggest a
cut-off score of 5 out of 30, representing possible pain
being present [22,23], but this has not been empirically
validated.
Despite a shortage of validation studies published in
international journals and despite a call for thorough val-
idation [25], including information on inter-rater reliabil-
ity [17], the French version of the Doloplus-2 is in
widespread clinical use in France and Switzerland [23].
This prompted us to undertake a Norwegian pilot valida-
tion study in 2004, in which we evaluated 59 patients who
were institutionalized in nursing home units for the
demented [24]. While well established protocols are avail-
able for the validation of self-report based assessment
tools there is no consensus on how to validate tools for
observational assessment. The objective of this pilot study
was to translate the Doloplus-2 from French into Norwe-
gian, to test the translation, explore the user-experiences,
and evaluate the criterion validity of the Doloplus-2. The
aim was to test the Doloplus-2 in patients who were una-
ble to self-report and therefore we compared nurses' Dol-
oplus-2 scores to pain scores (pain criterion) given by
pain experts who examined these patients (R2 = 62%). The
results demonstrated satisfactory criterion validity in
some domains. The Doloplus-2 item for facial expressions
was the most informative, while the item for social life con-
tributed least. All the three items forming the psychosocial
domain (Communication, Social life, and Behavioural
problems) were reported as problematic to conceptualize
and contributed marginally to explain the expert pain
score [24]. These results were supported by a recent study
that evaluated the psychometric properties of the Dolo-
plus-2, and two other tools for behavioural pain assess-
ment, by comparing observer based pain scores from two
independent raters [26]. This study found low congruent
validity in the Doloplus-2, it questioned the validity of the
psychosocial domain, and its clinical usefulness was eval-
uated as moderate by the participating nurses. The authors
acknowledged that the study design was less adequate for
exploring the psychometric properties of the Dololplus-2
compared to the other tools and they requested more
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studies on the validity and intra- and inter-reliability of
the Doloplus-2 [26].
Based on the previous results and our experiences with the
use of a pain expert as a criterion for pain, a new study was
launched in order to further study the psychometric per-
formance of the Doloplus-2. The objectives of the present
study were to:
1. Assess the criterion validity of the Doloplus-2 in
patients who are unable to self-report pain due to cogni-
tive failure.
2. Test the inter-rater reliability of a pain expert's ratings
(used as criterion).
3. Evaluate the inter-rater reliability of the Doloplus-2 by
comparing the results from different and independent
administrators.
Methods
Subjects
The subjects were a convenience sample of 73 consecu-
tively recruited patients from two nursing homes (N = 51)
and from the Section of Geriatrics at St. Olav's University
Hospital (N = 22) in Trondheim, Norway. As previous
publications had demonstrated pain to be prevalent in
regular nursing homes and in geriatric hospital units
[3,27], these were approached under the assumption that
painful somatic conditions would be prevalent. The
patients should be unable to self-report pain due to cog-
nitive impairment based upon the nurses' clinical evalua-
tion of the patients. Pain was defined as and limited to
somatic pain, i.e. a symptom generally relieved by analge-
sics, and consequently excluding what the pain expert
interpreted as existential pain.
Baseline characteristics
Cognitive function was assessed by the Mini Mental State
Examination (MMSE) [28,29] administered by either a
ward nurse or a medical student. The MMSE rates the level
of cognitive function on a scale from 0–30. Patients with
scores from 30-21 are regarded as normal to mildly cogni-
tively impaired, scores from 20-11 denote moderate cog-
nitive impairment, and patients scoring 10-0 are severely
cognitively impaired [30]. The MMSE was performed
within the same week as the main data collection. At one
nursing home ward the MMSE was performed within a
month (N = 10). Due to the patients' stabile conditions
this was regarded as appropriate. Ability to perform activ-
ities of daily living (ADL) was evaluated by a nurse famil-
iar with the patient, using the Barthel Index [31]. This tool
describes the ability to perform ADL on a scale from 0–20.
Barthel index scores from 20-15 indicate independence to
mildly disabled ADL function, 14-10 indicate moderate
disability, while a score of 9-0 indicate that the patient is
severely to very severely disabled [32]. The Barthel Index
was completed within a week of the Doloplus-2. The
MMSE and Barthel Index measures were used to provide a
baseline characteristic of the patients' status. Information
regarding patients' use of analgesics was not recorded.
Because our aim was to test if the Doloplus-2 could assess
pain in those who experienced pain, it was not regarded
necessary to know if a low level of pain behaviours were
caused by adequate treatment or lack of pain.
Criterion validity of the Doloplus-2
The Doloplus-2 [22,24] is composed of ten items distrib-
uted on three domains: somatic, psychomotor and psy-
chosocial. The somatic domain has five items, while the
psychomotor and psychosocial domains have two and
three items, respectively. Each item has four response
alternatives, and is scored 0 for normal behaviour,
through to 3 for high levels of pain-related behaviour.
Thus the total Doloplus-2 score ranges from 0–30.
The Doloplus-2 was administered by trained enrolled
nurses, or registered nurses who were familiar with the
patient. The attending daytime nurse completed the Dol-
oplus-2 registration after consulting with the other
personnel who had been involved with the patient during
the past 24 hour period. Pain in the Doloplus-2 was regis-
tered according to the instructions for Doloplus-2 and
recorded once for each patient, usually between noon and
3 p.m. [22].
In line with psychiatric methods for observational assess-
ment and diagnoses in cases where an objective measure
is inaccessible a clinical expert statement was used as the
criterion for pain [33-35]. A pain specialist nurse (pain
expert) from the National Centre of Expertise for Pain and
Complex Disorders at St. Olav's University Hospital of
Trondheim made a single evaluation of each patient's
pain level on an eleven point Numerical Rating Scale
(NRS-11) from zero (no pain) to ten (worst imaginable
pain). Each patient was ascribed two pain intensity scores,
one for pain in movement and one for pain at rest. These
scores were used as the pain criterion. The pain evaluation
was performed the same day as the Doloplus-2 assess-
ment, usually between noon and 4 p.m. The expert's eval-
uation made use of information from the medical record,
reports from nurses and patients (if possible) about pain
during the past 24 hours, and a clinical examination. The
clinical examination comprised observation of the patient
during rest and activity, and examination of common trig-
ger points for pain. Both the expert's pain score and the
nurses' Doloplus-2 scores were based upon the same time
interval and all assessors had access to information about
the patient's medical condition during the past 24 hours.
BMC Geriatrics 2007, 7:29 http://www.biomedcentral.com/1471-2318/7/29
Page 4 of 9
(page number not for citation purposes)
The expert was blinded from the Doloplus-2 administra-
tors' assessment, and vice versa.
As a validation of the evaluations performed by the pain
expert, two geriatricians with expertise in pain presenta-
tion in demented patients observed the pain expert while
he evaluated 15 consecutive patients. Without discussing
the patients with the pain expert, the two geriatricians
independently rated the patients' pain using NRS-11.
Their ratings were later examined for degree of association
with the expert's ratings.
Inter-rater reliability
Inter-rater reliability of the Doloplus-2 was assessed in 16
patients consecutively included at the Section of Geriatrics
at St Olav's University Hospital. A geriatric specialist nurse
(GN) and an enrolled nurse evaluated each patient at the
same day and blinded from each other. The GN assessed
all patients, while a team of six different enrolled nurses
made the second assessment.
See Figure 1 for overview of the study procedure.
Analyses
Univariate regression analyses were performed in order to
analyse how well the Doloplus-2 predicted the expert pain
score (R-squared), and to analyse the contributions of
each of the ten items. Since the Doloplus-2 score maxi-
mizes pain by adding the scores of all items, we chose to
compare with the highest of the pain expert's scores. The
pain-in-movement score was higher than the pain-at-rest
score in all patients and consequently used as the pain
criterion.
Association between the expert's pain ratings and the two
geriatricians' ratings and the inter-rater reliability of the
Doloplus-2 were evaluated with intra-class correlation
coefficients. All analyses were performed by the SPSS sta-
tistical software version 13.0 (SPSS Inc., Chicago, USA).
Ethics
The Regional Committee for Medical Research Ethics
approved the study. As recommended by the committee,
written informed consent was not obtained from the
patients due to their cognitive impairment. Instead, the
patient's nearest relative was informed, both in writing
and orally, and asked to give consent. Eligible patients
were informed orally and asked if they would participate
before the administration of the MMSE and the pain
expert evaluation. Patients were not to be included if they
or their relative declined participation, but no one did.
The constructors of the Doloplus-2 have approved our use
of the tool.
Results
Baseline characteristics
Seventy-three patients were approached and all were
included. The mean age of the sample was 84 years (Table
1), and 74% were female. The median MMSE score was 10
(Table 1). Two subjects died before the MMSE assessment,
and seven were not assessed as they moved to another
nursing home before the MMSE assessment. These
patients were included in the pain analyses, but excluded
from the MMSE calculations. The Barthel Index scores had
a median value of 9 (Table 1).
Study procedureFigure 1
Study procedure. *Performed the same day, usually performed between noon – 3 p.m. **The MMSE and Barthel were per-
formed within the same week as the pain assessments except from ten MMSE that was performed within a month.
51 patients living 
in nursing homes
22 patients from a 
geriatric section at an 
university hospital
MMSE and Barthel**
Doloplus-2 and expert 
evaluation of pain for 
the past 24-hours, 
N=73* Inter-rater reliability in 16 consecutively 
Doloplus-2 
assessments
Validation of expert in 
15 consecutively pain 
evaluations
Pain assessments Patient samples Tests in sub-samples
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Validity of the Doloplus-2
The expert rated seven patients t 4 for pain-in-movement
(moderate-to-severe pain), 40 were rated 1–3, and 26
were rated as without pain. In all patients, the pain-in-
movement score was equal to or higher than the pain-at-
rest score. The association between the pain expert's rat-
ings and the two geriatricians' ratings (N = 15) was esti-
mated with an intra-class correlation of 0.74 with a 95%
confidence interval from 0.5 to 0.89.
The mean Doloplus-2 score was 7.47 (SD = 5.08) with a
range from 0–22. Five patients received a Doloplus-2
score of zero. Among these, three were also rated with no
pain by the expert, while the other two received a score of
zero at rest and two in movement.
The regression analysis of the Doloplus-2 scores against
the expert scores produced an R2 of 0.023, implying
poor criterion validity of the Doloplus-2 in this data set
(Figure 2).
To explore the data more closely we analysed each study
site separately. No significant results were obtained while
looking at the complete data from the three sites; how-
ever, association was found between the pain expert and
the geriatric expert nurse (GN) who administered the Dol-
oplus-2 in 16 patients in the Section of Geriatrics, with an
R2 of 0.54.
Univariate regression analyses of the different Doloplus-2
items (full sample) showed small but significant relation-
ships between the Doloplus-2 item for protective body pos-
tures at rest and the expert's pain-in-movement score (R2 =
0.12, p = 0.003) and for the Doloplus-2 item pain com-
plaints and the expert's pain-at-rest score (R2 = 0.13, p =
0.002).
Inter-rater reliability
The intra-class correlation for inter-rater reliability of the
Doloplus-2 administrators was 0.77, with a 95% confi-
dence interval of 0.47 – 0.92.
Discussion
Herr et al. (2004) called for extensive testing of the Dolo-
plus-2 to provide sufficient details on which to base
sound judgment of the tool, and a recent review ques-
tioned both the specificity of the Doloplus-2 and the
nurses' competence for scoring and interpreting the
results [17]. The present study failed to confirm a valid
relationship between the expert's ratings of pain and the
Doloplus-2 scores in a sample of 73 cognitively impaired
patients, even though the inter-rater reliability of the Dol-
oplus-2 seemed to be satisfactory. These results differ from
those of our previous pilot validation study [24], in which
acceptable criterion validity was demonstrated when com-
paring Doloplus-2 against expert ratings.
We acknowledge several limitations in the present study.
The samples sizes were small as indicated by the confi-
dence intervals for the inter-rater analyses and the major-
ity of the subjects were female (74%). Use of analgesics
was not recorded. Analgesic efficacy might fluctuate
throughout the day and information on the use of analge-
sics could have provided valuable baseline information.
However, since all patients were evaluated on the basis of
the full 24-hour period any potential bias from analgesics
should be equivalent in both the expert and in the Dolo-
plus-2 assessments.
The use of a pain expert's rating as a pain criterion is dis-
putable as it may be questioned whether this represents a
valid criterion. In line with psychiatric methodology for
cases where no obvious gold standard exists, we used an
expert-evaluation of the patients as the pain criterion. We
tested the expert's performance in a sub-sample (N = 15)
and found satisfactory inter-rater reliability between the
expert and the two geriatricians. The low end of the confi-
dence interval for the inter-rater reliability indicates that
despite the small sample size of 15 evaluations the agree-
ment is satisfactory.
It is probably an advantage for an expert-rater to know the
patients. In the pilot study, the physicians responsible for
the patients' treatment acted as the expert [24]. It is possi-
ble that the lack of association between Doloplus-2 and
the expert's rating in the present study may partly be due
to the use of an external pain expert who was unfamiliar
Table 1: Distribution frequencies of background variables
Age (mean 84) Numbers (N = 73)
69–79 years 19 (26%)
80–90 years 37 (51%)
> 90 years 17 (23%)
MMSE-Score (median 10)*
Severely cognitively 
impaired (CI)
0–10 32 (50%)
Moderately CI 11–20 23 (36%)
Mildly CI to normal 21–30 9 (14%)
Barthel Index-Score (median 9)
Very severely to 
severely disabled
0–9 41 (56%)
Moderately disabled 10–14 18 (25%)
Mildly disabled to 
independent in ADL
15–20 14 (19%)
*9-missing
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with the patients instead of one who was familiar with the
patients and the staff. The expert evaluated the presence of
pain at rest and in movement. The Doloplus-2 does not
distinguish between rest and movement, but adds all
scores together. We decided to use the higher obtained of
the two expert scores. This was without exception the
pain-in-movement score. We do not suggest that the Dol-
oplus-2 is designed to measure only pain in movement,
but we believe that the expert's pain-in-movement score is
the best indicator of pain in these patients.
Five patients were rated with a Doloplus-2 score of zero,
as opposed to 26 in the expert's ratings. In order to discuss
the discrepancy between Doloplus-2 and expert score, the
pain expert, the GN and the Doloplus-2 administrators at
one nursing home were consulted. It was impossible to
know whether the pain expert identified false negative
pain cases or whether the Doloplus-2 identified false pos-
itives. A general conclusion was that Doloplus-2 assess-
ment in many of these patients was perceived as difficult.
In patients who had high Doloplus-2 scores and low
expert scores, clinical examinations revealed that the
patients' discomfort seemed frequently related to grief,
depression, anxiety and/or agitation rather than to
somatic pain. This might suggest that the Doloplus-2
identifies patients with pain who may not have somatic
pain (i.e. false positives), on the other side we can not out
rule that this is a result from the pain expert underrating
pain. The Doloplus-2 administrators were instructed to
give positive scores on items only if changes in behaviour
were suspected to be pain-related. In practice however,
they were not able to evaluate this. As a result, they may
The relationship between expert ratings and Doloplus-2Figu e 2
The relationship between expert ratings and Doloplus-2. The scatter plot demonstrates the relationship between the 
expert's pain score (NRS-11) and the Doloplus-2 score (0–30) in all 73 patients.
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have given positive scores on behavioural changes proba-
bly related to other causes than pain. This illustrates some
well-known difficulties in pain assessment among
patients with Behavioural and Psychological Symptoms
of Dementia (BPSD) who are not able to describe their
problems thoroughly and who may also have atypical
symptom presentation [17,36]. The expert performed a
comprehensive evaluation of the patient, but his pain rat-
ings focused on what he judged as somatic pain intensity.
The Doloplus-2 approaches pain multidimensional and
this difference can partly explain some of the disagree-
ment between expert and Doloplus-2. A concern for the
validity of the expert judgments could be the use of
patient charts information to inform their judgments. Pre-
sumably, this would allow access to information about
physical pathology. There is only a marginal correlation
between physical pathology and self-report of pain in
people able to self-report. Inferring pain from this infor-
mation can be questionable. However, the pain expert has
several years experience from work at the National Centre
of Expertise for Pain and Complex Disorders at St. Olav's
University Hospital of Trondheim. A majority of the
patients coming to this clinic has pain that does not have
an identifiable basis in physical pathology. In the study
design we wanted to give the expert access to all available
information to minimize the chances of underestimating
pain. He evaluated the different sources of information
towards each other and we are confident in that he did not
underrate pain due to lack of information on physical
pathology in the charts. Instead, it may strengthen
the expert evaluation that the expert was informed about
the patients' diagnoses of possible painful chronic
conditions.
Analyses indicated that competence in geriatrics improved
the validity of the Doloplus-2 assessment. The Doloplus-
2 scores had higher correlations with the expert's pain rat-
ings in a small sub-group in which the Doloplus-2 was
administered by a specialist GN. This finding was in con-
cordance with the pilot study, where the Doloplus-2
administrators had higher skills than the administrators
in the present study, as all assessments were made jointly
by an enrolled nurse/registered nurse in cooperation with
a fully trained final-year medical student [24]. Thus, it
may be hypothesized that valid Doloplus-2 administra-
tion and interpretation demand training in geriatrics and
knowledge of pain presentation in cognitively impaired
patients. Analyses of the sub-group with the GN resulted
in a similar pattern of items contributing in explaining the
expert's pain score to that found in the pilot study [24].
The items for complaints, disturbed sleep, functionality
during washing/dressing, and facial expressions explained
most of the expert score, while the three psychosocial
items explained close to nothing. The Doloplus-2 was
originally developed for pain assessment in children and
the inclusion of the psychosocial items may come from
this origin. Based on results from Zwakhalen et al. (2007)
and our two studies we suggest that the psychosocial
domain could be removed from the Doloplus-2.
Some of the patients could provide limited information
about pain at the moment and this was demonstrated dur-
ing the expert's clinical examination and during the morn-
ing sessions, while the nurses wash and dress the patients,
which caused some patients to express pain complaints,
which then again lead to positive expert pain score and
positive score on the Doloplus-2 item about pain com-
plaints. The subjects' self-report was consequently taken
into account when it was available. Future studies could
try a simple verbal rating scale for self-report of pain
intensity in some patients and use this in a combination
with other criterions.
Reports have shown that pain is frequent, under-recog-
nised and under-treated in nursing homes. Therefore we
approached patients at regular nursing home units and at
a geriatric department in order to include patients with
higher levels of pain than in the pilot study [24]. As
expected the MMSE scores and the Barthel Index demon-
strated that the study population was cognitively impaired
and dependent on care. However, unexpectedly it turned
out that the sample had lower average levels of pain, as
rated by the experts than, the sample in the pilot study.
Low levels of pain have surprised other researchers in the
field [36]. Thus, the present study also failed to provide
data about the performance of Doloplus-2 in patients
with severe pain.
To validate a tool is a long process and solid conclusions
regarding the validity of the Doloplus-2 cannot be
reached on the basis of our two studies. Through our stud-
ies we have established some experience in the design of
studies for such validations. Future studies should include
some patients with known painful diagnoses like patients
with post operative hip-fractures. It will also be most val-
uable to have more than one pain criterion to test for
agreement, in those where self-report is invalid. Pain
experts could be used to establish a criterion. The use of
more than one expert, blinded or unblinded, in each
patient will strengthen the study. Test treatment with anal-
gesics in patients with suspected pain and use of other
behavioural tools and a verbal rating scale for present pain
intensity may be valuable amendments.
The lack of agreement between expert and Doloplus-2
might reflect a common challenge for pain measurement
in cognitively impaired by the use of behavioural assess-
ment tools. Other tools recommended for use in these
patients Abbey Scale [18], PADE [19], PAINAD [20], and
PACSLAC [21] have obvious similarities to the Doloplus-
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2. All tools cover facial expressions, abnormalities in body
postures/movements like guarding sore areas, impaired
movement and verbal expressions. These tools are con-
structed for administration by health care providers, but
to our knowledge none of them claim any criteria with
regard to the administrators' competence. All tools
include domains that are not only affected by pain. The
inclusion of BPSD increases the pain sensitivity in these
tools, but the specificity decreases. The consequence may
be that comprehensive training of administrators and
high administration skills is needed. The brief Checklist of
Nonverbal Pain Indicators (CNPI) [37] is another inter-
esting behavioural pain assessment tool, as it covers those
parts of the Doloplus-2 that performed most successfully
in our studies, but it needs further validation [17]. The
CNPI may be an alternative that should be thoroughly
tested before finally judged.
Conclusion
Based on the results from our two studies combined, we
recommend the use of more than one pain criterion. Pain
experts can be used as one of these, especially in patients
that have no or limited ability to self-report. A combina-
tion of pain experts, other behavioral pain assessment
tools, a verbal rating scale for self-report of present pain
intensity and test-treatment with analgesics could consti-
tute a promising pain criterion in future studies. The
present study does not support the criterion validity of the
Doloplus-2 as a clinical pain assessment tool in its present
version. The results indicate that there seems to be a need
for systematic training of the administrators before the
instrument can be of clinical use.
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1. Barthel index 
2. Brief pain inventory 
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Barthel's index of activities of daily 
living (BAI) 
1. Bowel 
status
(Question 1 
of 10)
0 points - Incontinent (or needs to be given enema)
1 point - Occasional accident (once a w eek)
2 points - Fully Continent
2. Bladder 
status
(Question 2 
of 10)
0 points - Incontinent or catheterized and unable to manage
1 point - Occasional accident (max once per 24 hours
2 points - Continent (for more than seven days)
3.
Grooming
(Question 3 
of 10)
0 points - Needs help w ith personal care: face/ hair/ teeth / shaving
1 point - Independent (implements provided)
4. Toilet 
Use
(Question 4 
of 10)
0 points - Dependent
1 point - Needs some help but can do something alone
2 points - Independent (on and off/ w iping/ dressing)
5. Feeding
(Question 5 
of 10)
0 points - Unable
1 point - Needs help in cutting / spreading butter/ etc.
2 points - Independent (food provided w ithin reach)
6. Transfer
(Question 6 
of 10)
0 points - Unable (as no sitting balance)
1 point - Major help (physical/ one or tw o people)
2 points - Can sit minor help (verbal or physical)
3 points - Independent
7. Mobility
(Question 7 
of 10)
0 points - Immobile
1 point - Wheelchair-independent (including corners etc)
2 points - Walks w ith help of one person (verbal or physical)
3 points - Independent
8. Dressing
(Question 8 
of 10)
0 points - Dependent
1 point - Needs help but can do about half unaided
2 points - Independent (including buttons/ zips/ laces/ etc.)
9. Stairs
(Question 9 
of 10)
0 points - Unable
1 point - Needs help (verbal/ physical/ carrying aid)
2 points - Independent up and dow n
10. Bathing
(Question
10 of 10)
0 points - Dependent
1 point - Independent bathing or show ering
Reset
Barthel
Score (max 
20):
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DOLOPLUS-2 SCALE BEHAVIOURAL PAIN ASSESSMENT IN THE ELDERLY
Behavioural Records
NAME : Christian Name : Unit :
1• Somatic 
complaints
2• Protective 
body postures
adopted at rest
3• Protection of
sore areas
4• Expression
5• Sleep pattern
6• washing 
&/or
dressing
7• Mobility
8• Communication
9• Social life
10• Problems of
behaviour
SCORE
DATES
SOMATIC REACTIONS
PSYCHOMOTOR REACTIONS
PSYCHOSOCIAL REACTIONS
• no complaints  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 0 0
• complaints expressed upon inquiry only  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1 1
• occasionnal involuntary complaints  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2 2 2
• continuous involontary complaints . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 3 3
• no protective body posture  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 0 0
• the patient occasionally avoids certain positions  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1 1
• protective postures continuously and effectively sought  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2 2 2
• protective postures continuously sought, without success  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 3 3
• no protective action taken  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 0 0
• protective actions attempted without interfering against any investigation or nursing  . . . . . . . . . . . . . . 1 1 1 1
• protective actions against any investigation or nursing  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2 2 2
• protective actions taken at rest, even when not approached  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 3 3
• usual expression  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 0 0
• expression showing pain when approached . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1 1
• expression showing pain even without being approached  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2 2 2
• permanent and unusually blank look (voiceless,staring, looking blank)  . . . . . . . . . . . . . . . . . . . . . . . 3 3 3 3
• normal sleep . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 0 0
• difficult to go to sleep . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1 1
• frequent waking (restlessness)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2 2 2
• insomnia affecting waking times . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 3 3
• usual abilities unaffected . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 0 0
• usual abilities slightly affected (careful but thorough)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1 1
• usual abilities highly impaired, washing &/or dressing is laborious and incomplete  . . . . . . . . . . . . . . 2 2 2 2
• washing &/or dressing rendered impossible as the patient resists any attempt  . . . . . . . . . . . . . . . . . . 3 3 3 3
• usual abilities & activities remain unaffected  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 0 0
• usual activities are reduced (the patient avoids certain movements and reduces his/her walking distance) . 1 1 1 1
• usual activities and abilities reduced (even with help, the patient cuts down on his/her movements)  . . . . 2 2 2 2
• any movement is impossible, the patient resists all persuasion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 3 3
• unchanged  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 0 0
• heightened (the patient demands attention in an unusual manner)  . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1 1
• lessened (the patient cuts him/herself off)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2 2 2
• absence or refusal of any form of communication  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 3 3
• participates normally in every activity (meals, entertainment, therapy workshop)  . . . . . . . . . . . . . . . . . 0 0 0 0
• participates in activities when asked to do so only  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1 1
• sometimes refuses to participate in any activity  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2 2 2
• refuses to participate in anything  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 3 3
• normal behaviour  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 0 0
• problems of repetitive reactive behaviour  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1 1
• problems of permanent reactive behaviour  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2 2 2
• permanent behaviour problems (without any external stimulus) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 3 3
Somatic complaints
The patients expresses pain by word, gesture, cries, tears or moans.
Protective body postures adopted at rest
Unusual body positions intended to avoid or relieve pain.
Protection of sore areas
The patient protects one or several areas of his/her body by a defensive attitude or gestures.
Expression
The facial expression appears to express pain (grimaces, drawn, atonic) as does the gaze (fixed
gaze, empty gaze, absent, tears).
Investigation
Any investigation whatsoever (approach of a caregiver, mobilization, care procedure, etc.).
Washing/dressing
Pain assessment during washing and/or dressing, alone or with assistance.
Mobility
Evaluation of pain in movement: change of position, transfer, walking alone or with assistance.
Communication
Verbal or non-verbal.
Social life
Meals, events, activities, therapeutic workshops, visits, etc.
Problems of behaviour
Aggressiveness, agitation, confusion, indifference, lapsing, regression, asking for euthanasia, etc.
DOLOPLUS-2 SCALE : LEXICON
1 • Scale use requires learning
As is the case with any new instrument, it is judicious to test it before circulating it. Scale scoring time
decreases with experience (at most a few minutes). Where possible, it is of value to appoint a reference
person in a given care structure.
2 • Pluridisciplinary team scoring
Irrespective of the health-care, social-care or home structure, scoring by several caregivers is preferable
(physician, nurse, nursing assistant, etc.). At home, the family and other persons can contribute using 
a liaison notebook, telephone or even a bedside meeting. The scale should be included in the 'care' 
or 'liaison notebook' file.
3 • Do not score if the item is inappropriate
It is not necessary to have a response for all the items on the scale, particularly given an unknown patient
on whom one does not yet have all the data, particularly at psychosocial level. Similarly, in the event of
coma, scoring will be mainly based on the somatic items.
4 • Compile score kinetics
Re-assessment should be twice daily until the pain is sedated, then at longer intervals, depending on the
situation. Compile score kinetics and show the kinetics on the care chart (like temperature or blood pressure).
The scale will thus become an essential argument in the management of the symptom and in treatment 
initiation.
5 • Do not compare scores on different patients
Pain is a subjective and personal sensation and emotion. It is therefore of no value to compare scores
between patients. Only the time course of the scores in a given patient is of interest.
6 • If in doubt, do not hesitate to conduct a test treatment with an appropriate analgesic
It is now accepted that a score greater than or equal to 5/30 is a sign of pain. However, for borderline
scores, the patient should be given the benefit of the doubt. If the patient's behavior changes following
analgesic administration, pain is indeed involved.
7 • The scale scores pain and not depression, dependence or cognitive functions
Numerous instruments are available for each situation. It is of primary importance to understand that the
scale is used to detect changes in behavior related to potential pain.
Thus, for items 6 and 7, we are not evaluating dependence or independence but pain.
8 • Do not use the DOLOPLUS 2 scale systematically
When the elderly patient is communicative and cooperative, it is logical to use the self-assessment instruments.
When pain is patent, it is more urgent to relieve it than to assess it ... However, if there is the slightest
doubt, hetero-assessment will avoid underestimation.
DOLOPLUS-2 SCALE : INSTRUCTIONS FOR USE
DOLOPLUS - 2 Observasjonsbasert smerteskala for eldre
Etternavn: Fornavn: Avdeling:
Dato:Senternummer: Pasientnummer: 
SOMATISKE REAKSJONER 
1. Klager på smerte - ingen klager 0 0 0 0
- klager bare ved forespørsel/kontakt/undersøkelse 1 1 1 1
- spontane klager av og til 2 2 2 2
- vedvarende klager 3 3 3 3
2. Smertelindrende - benytter ingen smertelindrende hvilestillinger 0 0 0 0
hvilestillinger - unngår av og til enkelte hvilestillinger 1 1 1 1
- benytter vedvarende og effektive smertelindrende stillinger 2 2 2 2
- stadige virkningsløse posisjonskift (finner ikke ro) 3 3 3 3
3. Beskytter smertefulle - ingen beskyttelse 0 0 0 0
områder - beskytter seg, men tillater stell/undersøkelse 1 1 1 1
- beskyttelse som hindrer stell/undersøkelse 2 2 2 2
- beskytter seg også i fravær av kontakt 3 3 3 3
4. Ansiktsuttrykk - normalt ansiktsuttrykk 0 0 0 0
- ansiktsuttrykk som uttrykker smerte ved forespørsel/kontakt/undersøkelse 1 1 1 1
- ansiktsuttrykk som uttrykker smerte spontant 2 2 2 2
- vedvarende uttrykksløst ansikt (matthet, stivhet, tomt blikk) 3 3 3 3
5. Søvn - normal søvn 0 0 0 0
- problemer med innsovning 1 1 1 1
- hyppige oppvåkninger (urolig søvn) 2 2 2 2
- søvnløshet som påvirker våken tilstand 3 3 3 3
PSYKOMOTORISKE REAKSJONER 
6. Stell og/eller påkledning - aktivitet/bevegelighet er uendret (normalt) 0 0 0 0
- aktivitet/bevegelighet er litt hemmet, men lar seg gjennomføre 1 1 1 1
- aktivitet/bevegelighet er betydelig hemmet (vanskelig å gjennomføre) 2 2 2 2
- umulig, pasienten motsetter seg ethvert forsøk 3 3 3 3
7. Forflytning - forflytter seg som vanlig 0 0 0 0
- lett redusert (unngår enkelte bevegelser, begrenset gå-radius) 1 1 1 1
- sterkt redusert (selv med hjelp er forflytning vanskelig) 2 2 2 2
- forflytning er umulig, pasienten lar seg ikke overtale  3 3 3 3
PSYKOSOSIALE REAKSJONER 
8. Kommunikasjon - normal kommunikasjon 0 0 0 0
- intensivert kommunikasjon, søker oppmerksomhet på uvanlige måter 1 1 1 1
- redusert kommunikasjon (vil være alene) 2 2 2 2
- fravær eller avvisning av all kommunikasjon 3 3 3 3
9. Sosialt aktivitet - normal deltakelse i aktiviteter (måltider, tilstelninger osv.) 0 0 0 0
- deltar i aktiviteter, men kun etter overtalelse 1 1 1 1
- nekter av og til å delta i aktiviteter 2 2 2 2
- avstår fra all sosial aktivitet 3 3 3 3
10. Atferdsproblemer - normal atferd 0 0 0 0
- gjentatte atferdsproblemer 1 1 1 1
- permanente atferdsproblemer i kontakt med andre 2 2 2 2
- permanente atferdsproblemer (selv uten ekstern stimulans/kontakt) 3 3 3 3
TOTALT   
DOLOPLUS SKALA NØKKELORD
Klager
Pasienten uttrykker smerte ved tale, kroppsspråk (tegn/mimikk), utrop, gråt, stønning og/eller 
jamring. 
Smertelindrende stillinger 
Uvanlig kroppsstilling for å unngå eller lindre smerte. 
Beskyttelse av smertefulle områder 
Pasienten beskytter én eller flere deler av kroppen ved å innta en forsvarsposisjon og/eller ved 
beskyttende/avvergende bevegelser. Ikke skår hvis du mistenker at det er angst som utløser 
atferden. Mange demente vil beskytte seg når de ikke forstår hva som skal skje og dette skal 
ikke skåres. 
Ansiktsuttrykk
Ansiktet uttrykker smerte ved grimaser, mimikk (stram, sammenbitt eller uttrykksløst) og ved 
blikk (stirrende, fraværende, tårefylt, bedende, sint, desperat, engstelig eller fortvilet). Noen 
demente har vedvarende uttrykksløst ansikt som en konsekvens av sin demens, se derfor etter 
forandringer i forhold til det normale for pasienten når du skårer. 
Forespørsel/Kontakt/Undersøkelse
Alle former for konfrontasjoner; undersøkelse, tilnærming (innblanding), henvendelser,
omtanke, behandling og stell. 
Stell/påkledning
Vurdering av smerte under stell (eventuelt toalettbesøk) og/eller påkledning alene eller ved 
hjelp.
Bevegelser
Vurdering av smerte ved bevegelser; endring av stilling/posisjon, forflytning, gange; alene 
eller ved hjelp. 
Kommunikasjon
Verbal eller nonverbal. Se etter forandringer fra pasientens normale kommunikasjonsmønstre. 
Sosial aktivitet 
Måltider, tilstelninger, aktiviteter, terapeutisk behandling og besøk. 
Atferdsproblemer 
Aggressivitet, uro (rastløshet), forvirring, likegyldighet, regresjon, spørsmål om aktiv 
dødshjelp osv. Se spesielt etter forandringer i normale atferdsmønstre som kan skylles smerte.
DOLOPLUS SKALA: BRUKERVEILEDNING
1. Bruk forutsetter opplæring 
Som ved et hvilket som helst nytt instrument, er det klokt å prøve det ut før man setter i gang. 
Noteringstiden reduseres ved erfaring (maks. noen få minutter.) Hvis det er mulig, er det lurt å 
øve seg på pasienter som allerede er henvist til et behandlingsopplegg.
2. Registrering i tverrfaglige grupper
Registrering fra flere pleiere (lege, sykepleier, hjelpepleier) er å foretrekke, uansett 
behandlingssted (offentlig, privat, hjemme). I hjemmet kan familien og andre pårørende delta. 
Skalaen integreres i pleiejournalen. 
3. Ikke kryss av ved tvil eller hvis spørsmålet er uegnet 
Det er ikke nødvendig å finne svar på alle deler av skalaen, særlig ikke overfor en ukjent 
pasient hvor man ikke kjenner alle data (spesielt på det psykososiale plan.) Ved for eksempel 
koma, registreres bare legemlige fakta.  
4. Rutiner
Re-evalueringen bør finne sted to ganger daglig inntil lindring av smertene; videre 
registrering er avhengig av den enkeltes situasjon. I forkant av behandling er det viktig å ha 
resultatene fra DOLOPLUS i pleiejournalen (på lik linje med temperatur og blodtrykk)
dermed kan man kartlegge plagene og igangsette egnet behandling. 
5. Ikke sammenlign resultatene til ulike pasienter 
Smerte er subjektivt. Sammenlikning av poengsum pasienter imellom har derfor ingen 
hensikt. Kun pasientens individuelle utvikling er av interesse.  
6. Ved tvil; ikke nøl med å sette i gang en testbehandling med smertestillende tiltak 
En skåre lik eller over 5 av 30, antyder smerte. I tilfeller med nærliggende poengsummer, bør 
man la tvilen komme pasienten til gode. (Hvis situasjonen forandres ved smertestillende 
tiltak, vil smerte være påvist). 
7. Skalaen avdekker smerte; ikke depresjon, uselvstendighet eller kognitiv funksjon 
Det finnes passende måleinstrumenter for alle symptomer, men det er viktig å forstå at man 
her prøver å fange opp atferdsforandringer knyttet til eventuell smerte; punkt 6 og 7 evaluerer 
bare smerte, ikke grad av selvstendighet. 
8. Ikke bruk DOLOPLUS 2 - skalaen i alle tilfeller 
Hvis pasienten er kommunikativ og samarbeidsvillig, er det naturlig å bruke instrumenter for 
selvrapportering. Dersom smerte er innlysende, er det viktigere å lindre enn å evaluere. 
Likevel, hvis det er noen som helst tvil, er det bedre med en DOLOPLUS evaluering enn en 
undervurdering av pasientens smertetilstand. 
EORTC QLQ C30
p1. of 2
We are interested in some things about you and your health. Please answer all of these questions
yourself by ticking the alternative that best applies to you. There are no "right" or "wrong" answers. The
information that you provide will remain strictly confidential.
1. Do tou have any trouble doing strenuous activities,
like carrying a heavy shopping bag or a suitcase?
2. Do you have any trouble taking a long walk?
3. Do you have any trouble taking a short walk outside
of the house?
4. Do you need to stay in bed or a chair during the day?
5. Do you need help with eating, dressing, washing
yourself or using the toilet?
During the past week:
6. Were you limited in doing either your work or other
daily activities?
7. Were you limited in pursuing your hobbies or other
leisure time activities?
8. Were you short of breath?
9. Have you had pain?
10. Did you need to rest?
11. Have you had trouble sleeping?
12. Have you felt weak?
13. Have you lacked appetite?
14. Have you felt nauseated?
Not at
all
A
little
Quite
a bit
Very
much
Please go to the next page
Not at
all
A
little
Quite
a bit
Very
much
Draft
For the following question please tick the number between 1 and 7 that best applies to you.
29. How would you rate your overall health during the past week?
30. How would you rate your overall quality of life during the past week?
1 2 3 4 5 6 7
Versjon 3.0 1995©Copyright EORTC Study Group on Quality of Life. All rights reserved.
   During the past week:
1 2 3 4 5 6 7
Very poor    Excellent
Very poor    Excellent
15. Have you vomited?
16. Have you been constipated?
17. Have you had diarrhea?
18. Were you tired?
19. Did pain interfere with your daily activities?
20. Have you had difficulty in concentrating on things,
like reading a newspaper or watching TV?
21. Did you feel tense?
22. Did you worry?
23. Did you feel irritable?
24. Did you feel depressed?
25. Have you had difficulty remembering things?
26. Has your physical condition or medical treatment
interferred with your family life?
27. Has your physical condition or medical treatment 
interferred with your social activities?
28. Has your physical condition or medical treatment 
caused you financial difficulties?
Not at
all
A
little
Quite
a bit
Very
much
EORTC QLQ C30
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The Karnofsky Performance Scale Index allows patients to be classified as to 
their functional impairment. This can be used to compare effectiveness of 
different therapies and to assess the prognosis in individual patients. The lower 
the Karnofsky score, the worse the survival for most serious illnesses.  
KARNOFSKY PERFORMANCE STATUS SCALE DEFINITIONS 
RATING (%) CRITERIA 
  100 Normal no complaints; no evidence of disease. 
90
Able to carry on normal 
activity; minor signs or 
symptoms of disease. 
Able to carry on normal activity and to 
work; no special care needed. 
80
Normal activity with effort; 
some signs or symptoms of 
disease.
70
Cares for self; unable to carry 
on normal activity or to do 
active work. 
60
Requires occasional assistance, 
but is able to care for most of 
his personal needs. 
Unable to work; able to live at home 
and care for most personal needs; 
varying amount of assistance needed. 
50
Requires considerable 
assistance and frequent medical 
care.
40 Disabled; requires special care and assistance. 
30
Severely disabled; hospital 
admission is indicated although 
death not imminent. 
20
Very sick; hospital admission 
necessary; active supportive 
treatment necessary. 
10 Moribund; fatal processes progressing rapidly. 
Unable to care for self; requires 
equivalent of institutional or hospital 
care; disease may be progressing 
rapidly.
0 Dead
MINI MENTAL STATE 
      EXAMINATION
             (MMSE)
Patient's name:
Hospital number:
ORIENTATION
REGISTRATION
ATTENTION AND CALCULATION
RECALL
LANGUAGE
COPYING
Year    Month     Day     Date     Time
Country     Town      District     Hospital     Ward
Examiner names 3 objects (eg apple, table, penny)
Patient asked to repeat (1 point for each correct).
Subtract 7 from 100,  then repeat from result.
Continue 5 times:  100  93  86  79  65
THEN patient to learn the 3 names repeating until
correct.
Ask for names of 3 objects learned earlier.
Name a pencil and watch.
Repeat "No ifs, ands, or buts".
Give a 3 stage command.  Score 1 for each stage.
Eg. "Place index finger of right hand on your nose
and then on your left ear".
Ask patient to read and obey a written command 
on a piece of paper stating "Close your eyes".
Ask the patient to write a sentence. Score if it is 
sensible and has a subject and a verb.
Ask the patient to copy a pair of intersecting
pentagons:
TOTAL
____/5
____/5 ____/5 ____/5
____/5
____/5____/5 ____/5
____/5 ____/5
____/5____/5
____/2
____/1
____/3 ____/3 ____/3
____/2 ____/2 ____/2
____/1 ____/1 ____/1
____/3
____/3____/3 ____/3 ____/3
____/3 ____/3 ____/3 ____/3
____/1 ____/1 ____/1 ____/1
____/1____/1
____/1 ____/1
____/1 ____/1
____/1____/1
DATE
____/30 ____/30
____/30 ____/30
ONE POINT FOR EACH ANSWER
Alternative: spell "WORLD" backwards - dlrow.
Ekspertvurdering DOLOPLUS-studien 
Pasientnummer:                              Senternummer: 
Senternummer: Bromstad =  1        Furuveien = 2       Persaunet D2 = 3       Persaunet 
D3 = 4 
Vennligst sett ring rundt det tallet som best beskriver pasientens smerteintensitet i ro
0 1       2       3       4       5    6      7       8       9       10 
Ingen smerter               Verst tenkelige smerter 
Vennligst sett ring rundt det tallet som best beskriver pasientens smerteintensitet i
bevegelse 
0 1       2       3       4       5    6      7       8       9       10 
Ingen smerter               Verst tenkelige smerter
Eventuelle kommentarer: 
Responses of the assessor to the DOLOPLUS questionnaire. 
Please fill in how you experienced using the DOLOPLUS questionnaire. By 
“difficulty” we mean any practical problems you encountered with this item. 
Confusing is about the wording of the item, and whether it could be ambiguous. Tick 
the box for “difficult words” if you think it was difficult to understand the content of 
the item. Please let us know how you would have asked the question if you don’t like 
the suggested wording. 
Thanks a lot for your contribution! 
Comments
Question 1: Somatic complaints 
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
      _________________________________ 
      _________________________________ 
Question 2: Protective body postures adopted at rest 
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
      _________________________________ 
      _________________________________ 
Comments
Question 3: Protection of sore areas 
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
      _________________________________ 
      _________________________________ 
Question 4: Expression 
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
      _________________________________ 
      _________________________________ 
Comments
Question 5: Sleep pattern 
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
      _________________________________ 
      _________________________________ 
Question 6: Washing and/or dressing 
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
      _________________________________ 
      _________________________________ 
Comments
Question 7: Mobility 
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
      _________________________________ 
      _________________________________ 
Question 8: Communication 
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
      _________________________________ 
      _________________________________ 
Comments
Question 9: Social life 
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
      _________________________________ 
      _________________________________ 
Question 10: Problems of behaviour
a.   Difficulty?  Yes   _________________________________ 
      _________________________________ 
b.  Confusing?  Yes   _________________________________ 
      _________________________________ 
c.  Difficult words? Yes   _________________________________ 
      _________________________________ 
d.  How would you ask this question ?  _________________________________ 
Do you have general comments to the questionnaire? 
(Is it relevant for pain assessment? Was it relevant for your patients? Was 
it easy to implement in routine practice? Etc etc …) 
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
_____________________________________________________
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